


CANCER INCIDENCE DATA SRI LANKA- 2011



Tracheal bronchus in lung 0.5%

Demolition 7.6%

Esophagus and rectum

Table 01: Cancer Incidence in Sri Lanka-2011

	Number	%	CI	ASR
Male	9970	47.9	20.6	20.4
Female	9117	52.1	26.7	26.2
Total	17682	100.0	23.7	23.2

Sex	ASR
Male	20.4
Female	26.2
Total	23.2

NATIONAL CANCER CONTROL PROGRAMME
MINISTRY OF HEALTH, NUTRITION & INDIGENEOUS MEDICINE

Cancer Incidence Data

Sri Lanka 2011



National Cancer Control Programme

555/5, Elvitigala Mawatha
Narahenpita, Colombo 5
Sri Lanka

ISBN: 978-955-3666-34-5

National Cancer Control Programme 2018

13th Publication

Printed by P&G Printers (Pvt) Ltd (2 447722)

Contributors

Data Collection

Dr. Suraj Perera	Dr. G. I.D.D. Karunarthna
Dr. K. G. Nirmala Jayanthi	Dr. Harshani Hewavitharana
Dr. Asanga Hemaratne	Dr. J.M.M.A. Jayasinghe
Dr. Pushpika Samarakoon	Dr. S.M.K.I.C. Kapugedara
Dr. Ruwanmalee Liyanagama	Dr. Subadarshan Gunasingam
Dr. Kamal Seneviratne	Dr. Dayashani wijethunga
Ms. Chamila Peiris	Dr. O.A.R.Kularatne
Dr. G.D.T. Kanchana	Dr. J.C.Jayasinghe
Dr. U.V.S.S. Amaradasa	Dr. W.K.T.D.Dewagiri
Dr. R.M.C.M.B. Ranasinghe	Dr. R.M.T.N.K.Rathnayake
Dr. J.C.N. Jayasinghe	Dr. M.N.Herath
Dr. T. Susitharan	Ms. A. Mirnalini
Ms. U.K.N.P. Ayagama	

Data Coding

Dr. K. G. Nirmala Jayanthi	Dr. Ruwanmalee Liyanagama
Dr. Asanga Hemaratne	Dr. L.D. Rathnasiri
Dr. Pushpika Samarakoon	Dr. Shreeni Alahapperuma
Dr. A.M.Uttara Amilani	Ms. Chamila Peiris

Verification

Dr. Pushpika Samarakoon	Dr. K.G. Nirmala Jayanthi
-------------------------	---------------------------

Data Entry

Ms.Nimesha Prasadi	Ms. Dilini Athukorala
Ms. Manori Wijeratna	Ms. Erandi Dias

Statistical Analysis and Report Writing

Dr. Suraj Perera	Dr. K.G. Nirmala Jayanthi
------------------	---------------------------

Support Staff

Mr. Saman Kumara Mahalekam	Mr. Sineth Eranga
Ms. Thushari Dammika	Mr. Manora Amarasena

GIS Maps

Dr. Prasad Ranaweera, Consultant Community Physician, Management and Planning unit,
Ministry of Health

Special Thanks

Prof. R. Swaminathan (Head, Department of Epidemiology, Bio statistics and Cancer Registry of WIA
Cancer Institute, Adyar, Chennai, India.)

Message from Director General of Health Services



I am pleased to release this message to the 'Cancer Incidence Data, Sri Lanka - 2011' published by the National Cancer Control Programme (NCCP) of Ministry of Health, Nutrition & Indigenous Medicine.

Cancer surveillance through registration of cancers parallelly is one of the key strategies of prevention & control of cancers. For programme planning, implementation including resource allocation as well as monitoring and evaluation of cancer control activities, cancer morbidity and mortality data is very important. Since cancer control is a priority activity under the global health agenda of Non-Communicable Disease control, comprehensive information generated through this publication covering entire country is highly valuable.

I would like to appreciate the regular technical support of WHO country office and the International Agency for Research on Cancer of WHO for expediting the publication of cancer incidence data in Sri Lanka. I also appreciate NCCP and the other stakeholders including oncology units, Oral-maxillo facial units and the pathology laboratories for their valuable contribution in this nationally important endeavour.

Dr. Anil Jasinghe

Director General of Health Services

Message from Deputy Director General of Non-Communicable Diseases



It is with great pleasure I send this message to the 'Cancer Incidence Data, Sri Lanka - 2011' published by the National Cancer Control Programme (NCCP).

This publication generates valuable information on cancer incidence for planning, implementing, monitoring and evaluation of cancer control activities at national level & sub national levels. Therefore, the information published in this edition will be beneficial for the national and provincial health administrators in both curative and preventive health sectors, practicing clinicians and researchers.

The resolution on cancer control adopted in World Health Assembly in 2017 also encourages countries to take actions 'to collect high-quality population-based incidence and mortality data on cancer, for all age groups by cancer type, including measurements of inequalities, through population-based cancer registries, household surveys and other health information systems in order to guide policies and plans'. Therefore, it is essential to work together to ensure the comprehensive and timely publication of cancer incidence data.

I wish to congratulate the Director, staff of National Cancer Control Programme and other stakeholders for their valuable contribution in generating this output despite various limitations.

Dr. Champika Wickramasinghe
Deputy Director General (NCD)

Foreword



The 'Cancer Incidence Data - Sri Lanka 2011' is the 13th of series of such publications done by the National Cancer Control Programme since 1990.

In order to improve the standards of this document, several changes were made in comparison to the previous publications. In this publication, the listing of cancers by the site is according to the ICD-10 code instead of the ICD-O codes. This complies with the practices of other international publications including 'Cancer Incidence in Five Continents' by the International Agency for Research on Cancer of World Health Organization.

Composite table with top ten cancers in each district was included to reflect the burden of cancer at district level. We hope that this will be useful for district level managers for decision making and programme planning. As well as this information will be useful for clinicians and other stakeholders to have a better insight into this important public health problem.

Cancer surveillance is one of the key functions of the National Cancer Control Programme. This is a tedious process which include, collection of cancer incidence data from different sources, coding and verification, entering them into the database, and then analysis and dissemination of data through this type of publication. This will not be successful if not all stakeholders provide their due contribution. I would like to express the gratitude of the National Cancer Control Programme for all of them who had done their duty diligently.

The National Cancer Control Programme is thankful to Professor R. Swaminathan, Head, Department of Epidemiology, Biostatistics and Cancer Registry of WIA Cancer Institute, Adyar, Chennai, India, one of the editors of the Volume 10 of the 'Cancer Incidence in Five Continents' for his excellent technical assistance while preparing this publication.

The World Health Organization has provided financial assistance to obtain technical support as well as for human resources for data extraction at cancer treatment centres and data entering at the center.

It is our wish that clinicians, public health specialists, administrators, policy makers and all other stakeholders will use data and information in this publication for better service delivery, programme planning and policy making. Any suggestions to improve the future reporting of cancer incidence data will also be very much appreciated.

Dr. Sudath Samaraweera
Director, National Cancer Control Programme

Table of Contents

	Page No.
Contributors	III
Message from Director General of Health Services	V
Message from Deputy Director General of Non-Communicable Diseases	VII
Foreword	IX
Table of Contents	XI
List of Tables	XI
List of Figures	XII
Executive summary	1
Introduction	2
Methodology	2
Cancer Incidence data - Table and Figures	05
Staging information of common cancers - 2011	65
List of References	96
Appendix Statistical Terminology	97

List of Tables

Table No.	Description	Page No.
01	General population: Sex distribution	5
02	Denominators used for calculations in the cancer registry	5
03	Statistics on doctors, hospitals and hospital beds	5
04	Cancer incidence by sex, 2006-2011	6
05	Deaths due to neoplasms at the hospitals, 2005-2011	7
06	Deaths due to neoplasms out of all registered deaths (hospital & field), 2005-2011	7
07	Cancer Incidence in Sri Lanka - 2011	8
08	Overall cancer incidence, by age and sex - 2011	8
09	Leading cancer sites - 2011	9
10	Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years) of leading cancer sites - 2011	10
11	Cancer cases by age group - Male 2011	17
12	Cancer cases by age group - Female 2011	20
13	Cancer cases by ethnicity, sex and sub-site - 2011	23
14	Age specific rates by site - Male 2011	26
15	Age specific rates by site - Female 2011	29
16	Lip, tongue and mouth - Incidence data 2011	32
17	Lip, tongue, mouth and pharynx- Incidence data 2011	34
18	Oesophagus-Incidence data 2011	37
19	Stomach - Incidence data 2011	38
20	Colon and rectum - Incidence data 2011	40
21	Larynx - Incidence data 2011	42
22	Trachea, bronchus and lung - Incidence data 2011	43
23	Skin - Incidence data 2011	45
24	Breast - Incidence data 2011	47
25	Cervix Uteri - Incidence data 2011	49
26	Uterus - Incidence data 2011	50
27	Ovary - Incidence data 2011	51
28	Prostate gland - Incidence data 2011	53
29	Urinary bladder - Incidence data 2011	54

Table No.	Description	Page No.
30	Thyroid gland - incidence data 2011	55
31	Lymphoma - Incidence data 2011	56
32	Leukaemia - Incidence data 2011	57
33	Cancer Incidence by site and histological type - 2011	58
34	Basis of diagnosis of cancer patients - 2011	66
35	Cancer treatment - 2011	67
36	Childhood cancer incidence data - 2011	69
37	Cancer incidence by geographical area - 2011	72
38	Cancer Incidence data by district - 2011	73

List of Figures

Figure No.	Description	Page No.
1	General population in Sri Lanka by 5-year age groups	5
2	Crude Incidence Rates-Sri Lanka, 2006 - 2011	6
3	Age Standardized Incidence Rates- Sri Lanka, 2006 - 2011	7
4	Cancer Incidence Rates - 2011	8
5	Age Specific Cancer Incidence rates - 2011	9
6	Proportion of leading cancers, male - 2011	11
7	Proportion of leading cancers, female - 2011	11
8	Leading cancers by age group, Male: 0-14 years	12
9	Leading cancers by age group, Female: 0-14 years	12
10	Leading cancers by age group, Male: 15-34 years	13
11	Leading cancers by age group, Female: 15-34 years	13
12	Leading cancers by age group, Male: 35-49 years	14
13	Leading cancers by age group, Female: 35-49 years	14
14	Leading cancers by age group, Male: 50-64 years	15
15	Leading cancers by age group, Female: 50-64 years	15
16	Leading cancers by age group, Male: 65 years & above	16
17	Leading cancers by age group, Female: 65 years & above	16
18	Age specific rates - Lip, tongue and mouth	33
19	ASR, 2006-2011, Lip, tongue and mouth	33
20	Age specific rates - Lip, tongue, mouth and pharynx	36
21	ASR, 2006-2011, Lip, tongue, mouth and pharynx	36
22	Age specific rates - Oesophagus	37
23	ASR, 2006-2011, Oesophagus	37
24	Age specific rates - Stomach	39
25	ASR, 2006-2011, Stomach	39
26	Age specific rates - Colon and rectum	41
27	ASR, 2006-2011, Colon and rectum	41
28	Age specific rates - Larynx	42
29	ASR, 2006-2011, Larynx	42
30	Age specific rates - Trachea, bronchus and lung	44
31	ASR, 2006-2011, Trachea, bronchus and lung	44
32	Age specific rates - Skin	46
33	ASR, 2006-2011, Skin	46
34	Age specific rates - Breast	48
35	ASR, 2006-2011, Breast	48

Figure No.	Description	Page No.
36	Age specific rates - Cervix uteri	49
37	ASR, 2006-2011, Cervix uteri	49
38	Age specific rates - Uterus	50
39	ASR, 2006-2011, Uterus	50
40	Age specific rates - Ovary	52
41	ASR, 2006-2011, Ovary	52
42	Age specific rates - Prostate gland	53
43	ASR, 2006-2011, Prostate gland	53
44	Age specific rates - Urinary bladder	54
45	ASR, 2006-2011, Urinary bladder	54
46	Age specific rates - Thyroid gland	55
47	ASR, 2006-2011, Thyroid gland	55
48	Age specific rates - Lymphoma	56
49	Age specific rates - Leukaemia	57
50	Stage at diagnosis - Breast cancer	65
51	Stage at diagnosis - Cervical cancer	65
52	Stage at diagnosis - Oral cancer	65
53	Basis of diagnosis - 2011	66
54	Percentage of patient who received different type of treatment	68
55	Cancer incidence by district - Male 2011	83
56	Cancer incidence by district - Female 2011	88
57	Cancer incidence by district - Male and Female 2011	93

Executive Summary

'Cancer Incidence Data Sri Lanka – 2011' is the 13th volume of the series of publication of cancer surveillance data of Sri Lanka. The newly diagnosed cancers in the year 2011 in Sri Lanka were considered for this publication. The data sources were 9 government cancer treatment centres, 13 pathology laboratories and 12 Oral and Maxillo-Facial (OMF) surgical units in the country. Sites of cancer and morphology of each cancer were coded according to the ICD-O3 coding guide. When processing the data, quality checks were conducted and duplicate entries were eliminated. When the cancer incidence data is analysed and presented, sites of cancers were classified according to the ICD 10 sites which is similar to the classification norms practice in the publication named '*Cancer Incidence in 5 continents*' by the International Agency of Research on Cancer (IARC) of World Health Organization (WHO).

In the year 2011, a total of 17,482 newly confirmed cancer cases were reported, giving a crude incidence rate (CR) of 83.7 per 100,000 population. Crude incidence rates of males and females were 80.6 /100,000 (n=8370) and 86.7/100,000 (n=9112). The highest 5-year age specific incidence rates were reported among males of 70-74 age group (512.6 /100,000) and females of 60-64 (424.8/100,000) age group. When age standardized rates (ASR) were considered, the overall ASR was 89.2/100,000 and the ASR for males and females were 90.4/100,000 and 88.7 /100,000 respectively. All three ASRs were increased by >2 /100,000 in relation to 2010 respective ASRs.

Lip, tongue and mouth (n=1524, CR=14.7/100,000), Lung (n=788, CR = 7.6/100,000), Oesophagus (n=608, CR=5.9/100,000) and Colo-rectal (n=523, CR = 5.0/100,000) were the highest incident cancers among males. Out of male leading incident cancers 18% were lip, tongue & mouth cancers. Breast (n=2419, CR=23.0/100,000), cervix (n=839, CR=8.0/100,000), thyroid (n=760, CR= 7.2/100,000), ovary (n=681, CR=6.5/100,000) were the highest incident cancers among females. Out of female leading incident cancers, 27% were breast cancers.

Out of all cancers nearly 96% cancers were diagnosed microscopically and histopathology details of the primary tumour were available for 84% of cancers. Staging information at diagnosis was available for 57% (n=1405) of breast cancers, 56% (n=469) of cervical cancers and 20% (n=383) of oral cancers. It is observed that 33% of breast cancers, 53% of cervical cancers and 77% of oral cancers were diagnosed at the advanced stages (Stage III or IV).

About 37% of patients have undergone surgery, 44% of patients have received radiotherapy and 51% have received chemotherapy for their cancer care.

The highest number of cancers were reported from Colombo (n=2077), Gampaha (n=1797), Kandy (n=1376), Kurunegala (n=1327) and Kalutara (n=988) districts.

When cumulative risk of developing cancer between the age group 0-74 is considered, one in every 10 male or female have a risk of developing cancer during their life time. The highest life time risk among females was for breast cancer (1 in 38) and for males it was for Lip, tongue & mouth cancer (1 in 51). However life time risk was 1 in 40 for breast cancer among females and lip, oral cavity and pharyngeal cancers among males in the year of 2010.

Cancer Incidence Data Sri Lanka - 2011

1. Introduction

Surveillance of cancers (registration of cancers) is one of the leading activities of prevention & control of cancers. The National Cancer Control Programme (NCCP) which was established in 1980 is the national focal point for surveillance of cancers in Sri Lanka. The information based on surveillance of cancers is disseminated as the publication named 'Cancer Incidence Data Sri Lanka'. Up to now 12 volumes have been published as shown in table (i).

Table (i) Summary details of previous 'Cancer Incidence Data Sri Lanka'

Year of cancer incidence data	Data generating centres						Publication	
	Cancer Treatment Centres	Pathology labs	OMF Units	Medical Record Rooms	Death Registrars	Total no. centres	Volume	Year published
1985	3	—	—	—	—	3	I	1990
1986	3	—	—	—	—	3	II	1991
1987	3	—	—	—	—	3	III	1993
1990	3	—	—	—	—	3	IV	1996
1995	3	—	—	—	—	3	V	2002
2000	4	—	—	—	—	4	VI	2006
2001-2005	5	—	—	—	—	5	VII	2009
2006	6	—	4	—	—	10	VIII	2012
2007	6	—	4	—	—	10	IX	2013
2008	7	16	17	—	—	40	X	2014
2009	9	15	17	—	—	41	XI	2015
2010	9	13	17	—	—	39	XII	2016

Current publication is the XIII (13th) volume of Cancer Incidence Data Sri Lanka.

2. Methodology

The process of surveillance of cancers includes collection of cancer incidence data from the point of diagnosis, point of treatment and point of death, coding of cancer incidence data, entering of cancer incidence data to the database, checking duplicates, verification of data, analysis of data and generation of information for dissemination through the publication of 'Cancer Incidence Data Sri Lanka'. At each step quality assurance is ensured.

2.1 Collection of cancer incidence data

2.1.1 Newly registered cancer patients at the cancer treatment centres

The cancer incidence data for the year 2011 was collected from the all 9 government cancer treatment centres as shown in table (ii).

Table (ii) Distribution of government cancer treatment centres

Category of hospitals	Names of the hospitals
National Hospitals	Apeksha Hospital (National Cancer Institute, Maharagama)
Teaching Hospitals	Kandy, Karapitiya, Anuradhapura, Batticaloa,
Provincial General Hospitals	Badulla, Rathnapura, Kurunegala
Base Hospital	Telippalai (Jaffna)

Relevant data were extracted from the cancer patients' clinic record files using 'Cancer Notification Form'. Data were extracted by the medical officers and nursing officers attached to the cancer units, trained pre-intern medical graduates and the staff of NCCP.

2.1.2 Newly detected cancers at the pathology laboratories

The newly detected cancer incidence data from pathology laboratories were received monthly through the 'Cancer Return Form - 1'. A total of **13 pathology laboratories** have sent relevant data for the year 2011 as shown in table (iii).

Table (iii) Distribution of pathology laboratories which have sent the details of newly diagnosed cancer patients

Category of hospitals	Names of the pathology laboratories
National Hospitals	National Hospital of Sri Lanka (NHSL), National Hospital for Respiratory Diseases (Chest Hospital), National Eye Hospital
Teaching Hospitals	De Soysa Hospital for Women, Castle Hospital for Women, Lady Ridgeway Hospital, Colombo North
Provincial General Hospitals	Kurunegala
District General Hospitals	Gampaha, Kalutara
University units	Faculty of Medicine –Jayawardenepura, Faculty of Medicine – Ruhuna, Faculty of Dental Sciences – Peradeniya

2.1.3 Newly diagnosed cancers at the Oral and Maxillo-Facial (OMF) Surgery Units

The data on newly confirmed cancer patients at the Oral and Maxillo-Facial units were received annually through the Oral Cancer Register maintained at the OMF units. A total of **12 OMF units** have sent the relevant data as shown in table (iv).

Table (iv) Distribution of OMF units which have sent the details of newly diagnosed cancer patients

Category of hospitals	Names of the hospitals
National Hospitals	Dental Institute-Colombo
Teaching Hospitals	Colombo North, Karapitiya, Kandy
Provincial General Hospitals	Badulla
District General Hospitals	Gampaha, Kalutara, Chilaw, Kegalle, Polonnaruwa
Base Hospitals	Kuliyapitiya, Panadura

2.2 Coding of cancer incidence data

The instructions of International Classification of Disease for Oncology 3rd edition (ICD-O 3) was used for topographical (site of cancer) and morphological (histological) coding of each cancer. The cancer registry staff at the NCCP coded the cancer incidence data.

2.3 Entering of cancer incidence data to the database

Coded cancer incidence data were entered into the CanReg5 database by the trained data entry operators attached to the NCCP. The data entering activities were closely supervised by the registry staff and regular feedback was given to ensure optimum quality.

2.4 Duplicate checking & verification of data

Initial quality and duplicate checking was conducted when entering and confirming the data to the CanReg5 data base. 'IARCcrgTools.zip' file programme was used to verify the cancer incidence data with site & histology. *Linkpro* software used by the Chennai Cancer Registry, Excel sheets and SPSS sheets were also used to identify duplicates. In addition, the data sources up to the patient clinic files were rechecked in the instances where errors were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were made before finalizing the data base for analysis.

2.5 Analysis of cancer incidence data

Analysis of cancer incidence data was conducted using MS Excel, SPSS software and the cancer registry analysis package developed using Foxpro software by the Chennai Cancer Registry. Analysis was conducted parallelly using above mentioned different software solutions to verify the results.

The analysed cancer incidence data are presented according to the latest standards practiced by the International Agency for Research on Cancer (IARC) of World Health Organization (WHO) when publishing cancer incidence data for the publication of 'Cancer Incidence in Five Continents (CI 5)'.

Therefore, the major changes of the presentation of cancer incidence data of this volume in comparison to previous volumes are shown in table (v)

Table (v) Variation of data presentation in cancer incidence data in comparison to previous volumes

	Current publication	Previous publication
1	<p>Classification of data according the site of cancer The ICD-10 codes were used to classify the data according to the site of cancer.</p>	<p>The ICD-O 3 codes were used to classify the data according to the site of cancer.</p>
2	<p>Grouping sites of cancer When sites of cancers were grouped, according to the ICD-10;</p> <p>(i) Lymphoma – C81 to C 85, C96</p> <p>(ii) Leukaemia - C91 to C95</p> <p>(iii) Other than lymphomas and leukaemias others were grouped as haemopoietic and reticuloendothelial cancers - D45 to D47</p>	<p>When sites of cancers were grouped according to the ICD-O;</p> <p>(i)Lymphoma – If the site of origin was in the lymph nodes coded to the C77. Extra nodal lymphomas were coded according to the site of origin.</p> <p>(ii) All leukaemias except myeloid sarcoma (M9930/3) were grouped to C42.1(bone marrow)</p> <p>(iii) Other haemopoietic and reticuloendothelial cancers were grouped to C42</p>
3	<p>Listing of 10 leading cancer sites When 10 leading cancer sites were listed, some ICD 10 sites were grouped together.</p> <p>C00 – C06 Lip, tongue and mouth cancer</p> <p>C07 – C08 Salivary Gland</p> <p>C12 – C13 Hypho pharynx</p> <p>C18 – C20 Colon and Rectum</p> <p>C23 – C24 Gallbladder</p> <p>C30 – C31 Nose and sinuses</p> <p>C33 – C34 Trachea, bronchus and lung</p> <p>C37 – C38 other thoracic organs</p> <p>C40 – C41 Bone</p> <p>C47 & C49 Connective and soft tissue</p> <p>C54 – C55 Uterus</p> <p>C70 – C72 Brain, nervous system</p> <p>C81 – C85 & C96 Lymphoma</p> <p>C91 – C95 Leukaemia</p>	<p>When 10 leading cancer sites were listed,</p> <p>C00 - C06 & C09-C014 were grouped together for oral cancer as 'Lip, oral cavity and pharynx cancer'</p>
	<p>C26, C39, C48, C76 & C80 – Other and unspecified</p> <p>C09, C10, C11, C12-C13 C14 were considered separately for calculating leading cancer sites.</p>	



Figure 01: General population in Sri Lanka by 5-year age groups

Table 01: General population: Sex distribution

Population ('000)	Year										
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
Male	9,359	9,350	9,475	9,678	9,782	9,889	9,956	10,060	10,148	10,249	10,381
Female	9,438	9,571	9,698	9,757	9,862	9,969	10,083	10,186	10,302	10,404	10,511
Sex Ratio ¹	99.2	97.7	97.7	99.2	99.2	99.2	98.7	98.8	98.5	98.5	98.8

¹Number of males per 100 females

Source: Department of Census and Statistics

Table 02: Denominators used for calculations in the cancer registry

Population ('000)	Year 2011
Male	10,381
female	10,511
Total	20,892

Source: Department of Census and Statistics

Table 03: Statistics on doctors, hospitals and hospital beds

(Government Institutions)


	Year									
	2001	2002	2003	2005	2006	2007	2008	2009	2010	2011
Doctors	9,135	10,157	NA	11,152	11,460	12,337	13,337	14,783	15,807	15,273
Population per MO	2,058	1,863	NA	1,764	1,733	1,625	1,518	1,491	1,410	1,366
Hospitals	569	576	607	608	614	615	647	642	636	638
Beds	57,946	59,144	59,262	61,594	67,021	68,694	67,942	70,842	72,506	73,939
Beds per 1000 population	3.1	3.1	3.1	3.2	3.4	3.4	3.4	3.5	3.5	3.5

NA-Not available

Source: Medical statistics Unit, Ministry of Health

Table 04: Cancer incidence by sex, 2006-2011

Year	Sex	Number	%	CR	ASR
2006	Male	6,205	44.1	62.7	69.2
	Female	7,875	55.9	79.0	79.5
	Total	14,080		70.9	74.2
2007	Male	6,356	46.6	63.8	70.9
	Female	7,279	53.4	72.2	72.8
	Total	13,635		68.0	71.6
2008	Male	7,695	46.6	76.5	85.5
	Female	8,816	53.4	86.6	88.0
	Total	16,511		81.6	86.4
2009	Male	7,858	46.5	77.4	86.4
	Female	9,030	53.5	87.7	89.1
	Total	16,888		82.6	87.5
2010	Male	7,993	47.1	78.0	87.4
	Female	8,970	52.9	86.2	87.7
	Total	16,963		82.1	87.3
2011	Male	8,370	47.9	80.6	90.4
	Female	9,112	52.1	86.7	88.7
	Total	17,482		83.7	89.2

**Figure 02: Crude Incidence Rates-Sri Lanka, 2006 - 2011**




Figure 03: Age Standardized Incidence Rates- Sri Lanka, 2006 - 2011

Table 05: Deaths due to neoplasms at the hospitals, 2005-2011

Year	No. of hospital deaths due to cancers	Crude annual death rate per 100,000 population	Proportionate Mortality Ratio (PMR) out of all hospital deaths
2005	2,753	14.0	8.3
2006	3,241	16.3	9.9
2007	3,498	17.5	10.1
2008	3,485	17.2	9.8
2009	3,774	18.5	10.0
2010	4,449	21.5	11.1
2011	4,631	22.2	11.8

Source: Annual Health Bulletin 2005 to 2011.

Table 06: Deaths due to neoplasms out of all registered deaths (hospital & field), 2005 - 2011

Year	Male			Female			Total		
	No.	CR	ASR	No.	CR	ASR	No.	CR	PMR
2005	4,983	50.9	57.0	4,420	44.8	45.8	9,403	47.9	7.1
2006	5,644	57.1	63.6	4,742	47.6	48.7	10,386	52.3	8.8
2007	5,827	58.5	65.4	4,804	47.6	48.8	10,631	53.1	8.9
2008*									
2009	6,105	60.2	67.6	5,181	50.3	52.0	11,286	55.2	8.8
2010	6,438	62.8	70.9	5,398	51.9	53.5	11,836	57.3	9.1
2011*									

Source: Registrar General's Department

* Not available


CR-Crude annual death rate due to cancers per 100,000 population

ASR – Age standardized annual death rate due to cancers per 100,000 population

PMR – Proportionate Mortality Ratio out of total deaths

Table 07: Cancer Incidence in Sri Lanka-2011

Sex	Number	%	CR	ASR
Male	8,370	47.9	80.6	90.4
Female	9,112	52.1	86.7	88.7
Total	17,482	100.0	83.7	89.2

**Figure 04: Cancer Incidence Rates-2011****Table 08: Overall cancer incidence, by age and sex-2011**

Age Group	Male			Female			Total		
	Cases	Population ('000)	Incidence	Cases	Population ('000)	Incidence	Cases	Population ('000)	Incidence
Unknown	21			21			42		
00-04	98	904	10.8	110	873	12.6	208	1,777	11.7
05-09	66	930	7.1	49	901	5.4	115	1,831	6.3
10-14	47	958	4.9	59	925	6.4	106	1,883	5.6
15-19	78	1,028	7.6	78	1,004	7.8	156	2,032	7.7
20-24	105	984	10.7	121	980	12.3	226	1,964	11.5
25-29	108	814	13.3	189	840	22.5	297	1,654	18.0
30-34	138	785	17.6	303	808	37.5	441	1,593	27.7
35-39	182	768	23.7	439	785	55.9	621	1,553	40.0
40-44	312	719	43.4	668	726	92.0	980	1,445	67.8
45-49	612	627	97.6	888	644	137.9	1,500	1,271	118.0
50-54	1,014	557	182.0	1,114	574	194.1	2,128	1,131	188.2
55-59	1,152	399	288.7	1,269	429	295.8	2,421	828	292.4
60-64	1,471	297	495.3	1,338	315	424.8	2,809	612	459.0
65-69	1,088	232	469.0	989	268	369.0	2,077	500	415.4
70-74	897	175	512.6	726	200	363.0	1,623	375	432.8
75+	981	204	480.9	751	239	314.2	1,732	443	391.0
Total	8,370	10,381	80.6	9,112	10,511	86.7	17,482	20,892	83.7




Figure 05: Age Specific Cancer Incidence Rates - 2011

Table 09: Leading cancer sites - 2011

Rank	Male				Female				Total			
	Site	No	CR	ASR	Site	No	CR	ASR	Site	No	CR	ASR
1	Lip, tongue and mouth	1,524	14.7	16.4	Breast	2,419	23.0	23.3	Breast	2,469	11.8	12.2
2	Trachea Bronchus and Lung	788	7.6	8.8	Cervix uteri	839	8.0	8.2	Lip, tongue and mouth	1,941	9.3	10.0
3	Oesophagus	608	5.9	6.7	Thyroid gland	760	7.2	6.8	Cervix uteri	839	8.0	8.2
4	Colon and rectum	523	5.0	5.7	Ovary	681	6.5	6.7	Ovary	681	6.5	6.7
5	Other and unspecified	489	4.7	5.3	Colon and rectum	591	5.6	5.8	Oesophagus	1,126	5.4	6.0
6	Prostate gland	480	4.6	5.5	Oesophagus	518	4.9	5.3	Colon and rectum	1,114	5.3	5.7
7	Larynx	454	4.4	4.9	Lip, tongue and mouth	417	4.0	4.1	Trachea Bronchus and Lung	978	4.7	5.2
8	Lymphoma	442	4.3	4.5	Uterus	411	3.9	4.1	Prostate gland	480	4.6	5.5
9	Leukaemia	374	3.6	3.9	Leukaemia	323	3.1	3.3	Thyroid gland	927	4.4	4.3
10	Stomach	285	2.7	3.1	Other and unspecified	311	3.0	3.1	Uterus	411	3.9	4.1
	All sites	8,370	80.6	90.4	All sites	9,112	86.7	88.7	All sites	17,482	83.7	89.2

CR - Crude rate per 100,000 population

ASR - Age standardized rate per 100,000 population

Table 10: Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years) of leading cancer sites - 2011

ICD 10 code	Site	Male		Female		Total	
		Cumulative Rate	Lifetime Risk	Cumulative Rate	Lifetime Risk	Cumulative Rate	Lifetime Risk
			(%) ¹		(%) ¹		(%) ¹
			(n) ²		(n) ²		(n) ²
C00-C06	Lip, tongue and mouth	1.99	1.97 (51)	0.51	0.51 (196)	1.22	1.21 (83)
C15	Oesophagus	0.85	0.84 (119)	0.68	0.68 (148)	0.76	0.76 (132)
C16	Stomach	0.38	0.38 (260)	0.14	0.14 (720)	0.26	0.26 (390)
C18-20	Colon and rectum	0.68	0.68 (147)	0.70	0.70 (143)	0.69	0.69 (145)
C32	Larynx	0.64	0.64 (156)	0.05	0.05 (2017)	0.33	0.33 (302)
C33-34	Trachea, bronchus and lung	1.15	1.14 (88)	0.21	0.21 (471)	0.66	0.65 (153)
C50	Breast	0.07	0.07 (1466)	2.65	2.62 (38)	1.40	1.39 (72)
C53	Cervix uteri	-	-	0.98	0.97 (103)	-	-
C54 & C55	Uterus	-	-	0.53	0.53 (190)	-	-
C56	Ovary	-	-	0.78	0.78 (128)	-	-
C61	Prostate gland	0.70	0.70 (143)	-	-	-	-
C73	Thyroid gland	0.16	0.16 (607)	0.67	0.67 (150)	0.42	0.42 (236)
C81-C85,C96	Lymphoma	0.51	0.51 (197)	0.31	0.31 (323)	0.41	0.40 (247)
C91-C95	Leukaemia	0.36	0.36 (279)	0.31	0.31 (325)	0.33	0.33 (301)
	All sites	10.92	10.35 (10)	10.19	9.69 (10)	10.51	9.98 (10)

1 - (%) - Lifetime risk as a percentage (per100 persons)

2 - (n) - Number of populations per one new case detected




Figure 06: Proportion of leading cancers, male - 2011




Figure 07: Proportion of leading cancers, female - 2011




Figure 08: Leading cancers by age group: Male, 0-14 years




Figure 09: Leading cancers by age group: Female, 0-14 years




Figure 10: Leading cancers by age group: Male, 15-34 years




Figure 11: Leading cancers by age group: Female, 15-34 years




Figure 12: Leading cancers by age group: Male, 35-49 years




Figure 13: Leading cancers by age group: Female, 35-49 years




Figure 14: Leading cancers by age group: Male, 50-64 years




Figure 15: Leading cancers by age group: Female, 50-64 years




Figure 16: Leading cancers by age group: Male, 65 years & above




Figure 17: Leading cancers by age group: Female, 65 years & above

Table 11: Cancer cases by age group - Male 2011

ICD 10 code and site	Age Groups																	Total
	Not kn	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C00 Lip	0	1	0	0	0	0	1	0	1	2	2	16	11	13	12	7	18	84
C01 Base of tongue	0	0	0	0	0	1	1	0	2	12	19	27	18	24	13	15	8	140
C02 Other and unspecified parts of tongue	0	0	0	0	0	0	2	2	7	25	46	73	46	65	32	32	35	365
C03 Gum	0	0	0	0	0	0	0	0	3	1	6	14	13	15	23	14	15	104
C04 Floor of mouth	0	0	0	0	0	0	0	2	1	6	16	20	24	24	13	9	12	127
C05 Palate	1	0	0	1	0	0	1	1	1	6	11	27	25	32	17	19	17	159
C06 Other and unspecified parts of mouth	1	0	0	0	0	0	2	3	6	16	43	54	90	96	70	69	95	545
C07 Parotid gland	1	0	0	0	1	4	0	1	4	0	1	3	4	2	3	4	0	28
C08 Other and unspecified major salivary gland	0	0	1	0	1	0	0	0	0	1	2	0	0	0	2	2	0	9
C09 Tonsil	0	0	0	0	0	0	0	0	3	7	17	27	25	28	9	9	11	136
C10 Oropharynx	0	0	0	0	0	0	0	0	2	3	10	27	15	23	12	12	8	112
C11 Nasopharynx	0	0	0	0	0	1	2	2	1	1	3	2	5	4	6	1	1	29
C12 Pyriform sinus	0	0	0	0	0	1	0	0	1	5	18	17	23	22	27	20	19	153
C13 Hypopharynx	0	0	0	0	0	0	0	1	1	1	4	6	4	8	9	5	4	43
C14 Other and ill-defined sites in the lip, oral cavity and pharynx	0	0	0	0	0	0	0	0	1	1	8	9	10	14	8	5	12	68
C15 Oesophagus	0	0	0	0	0	1	0	0	7	13	50	92	110	116	91	63	65	608
C16 Stomach	1	0	0	0	0	0	2	1	3	10	24	48	42	65	35	26	28	285
C17 Small intestine	0	0	0	0	0	0	0	0	0	1	4	1	1	2	3	5	0	17
C18 Colon	1	0	0	0	0	2	1	8	9	12	15	30	35	40	32	14	29	228
C19 Rectosigmoid junction	0	0	0	0	0	0	0	1	2	1	3	5	3	13	4	4	5	41
C20 Rectum	0	0	0	0	0	1	1	6	8	6	14	23	38	53	32	34	38	254
C21 Anus and anal canal	1	0	0	0	0	0	0	1	0	3	2	8	4	10	11	3	5	48
C22 Liver and intrahepatic bile ducts	3	3	2	1	2	0	1	2	6	5	13	11	15	26	18	20	14	142
C23 Gallbladder	0	0	0	0	0	0	0	0	1	1	2	1	2	1	0	1	0	9
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	0	0	0	0	2	3	10	3	8	4	4	1	35
C25 Pancreas	0	0	0	0	0	0	0	1	0	5	5	1	11	13	6	5	4	51
C26 Other and ill-defined digestive organs	0	0	0	0	1	0	0	0	0	0	1	2	0	2	1	0	1	8
C30 Nasal cavity and middle ear	0	0	0	0	0	1	0	1	0	1	3	2	3	4	4	2	4	25
C31 Accessory sinuses	0	1	0	0	1	0	0	1	0	1	1	2	3	4	1	4	2	21
C32 Larynx	1	0	0	0	0	0	0	1	4	13	37	69	85	81	60	58	45	454
C33 Trachea	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	0	0	4
C34 Bronchus and lung	1	0	0	0	1	1	1	1	4	26	35	98	129	184	135	84	84	784
C37 Thymus	0	0	0	0	0	0	0	1	3	0	0	1	0	2	1	2	0	10
C38 Heart, mediastinum and pleura	0	1	0	0	1	4	3	0	2	1	0	1	1	2	0	1	0	17

ICD 10 code and site	Age Groups																	Total
	Not kn	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C39 Other and ill-defined sites intrathoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C40 Bone and articular cartilage of limbs	0	0	1	4	10	5	2	0	2	3	1	3	3	0	0	1	0	35
C41 Bone and articular cartilage of other and unspecified sites	1	0	0	1	1	4	3	1	2	0	4	2	2	2	0	0	2	25
C43 Melanoma of skin	0	0	0	0	0	0	0	2	0	1	1	3	3	3	6	7	2	28
C44 Other malignant neoplasms of skin	0	0	0	0	0	1	2	1	3	7	14	17	21	21	24	15	23	149
C45 Mesothelioma	0	0	0	0	0	0	0	0	1	0	0	2	0	2	1	0	0	6
C47 Peripheral nerves and autonomic nervous system	0	0	0	0	0	2	0	2	1	2	1	1	2	2	0	1	0	14
C48 Retroperitoneum and peritoneum	0	2	0	0	1	1	0	1	0	1	1	0	0	2	1	0	1	11
C49 Connective, subcutaneous and other soft tissues	1	2	2	2	1	6	2	5	3	5	8	8	2	5	11	8	6	77
C50 Breast	0	0	1	0	0	0	0	0	2	3	4	6	3	10	7	7	7	50
C60 Penis	0	0	0	0	0	0	0	2	2	0	8	9	12	12	10	7	8	70
C61 Prostate gland	1	0	0	0	0	0	1	0	1	0	2	12	39	78	99	103	144	480
C62 Testis	0	4	0	1	10	9	11	7	7	3	2	4	0	1	1	1	0	61
C63 Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	3
C64 Kidney	0	4	5	0	0	1	0	5	4	4	5	13	11	20	19	4	8	103
C66 Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2
C67 Bladder	0	0	0	0	0	0	0	2	1	2	7	21	32	58	42	28	50	243
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	3
C69 Eye and adnexa	0	12	3	0	0	0	1	1	0	0	1	0	3	0	0	1	1	23
C70 Meninges	0	0	0	0	0	0	0	0	0	1	0	1	1	2	0	0	1	6
C71 Brain	0	5	11	4	6	8	11	10	11	15	17	21	16	14	11	9	3	172
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	3
C73 Thyroid gland	0	1	2	2	2	11	9	21	23	12	17	11	23	18	5	7	3	167
C74 Adrenal gland	0	12	1	1	0	0	1	0	0	1	1	1	1	1	0	0	0	20
C75 Other endocrine glands and related structures	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	1	3
C76 Other and ill-defined sites	0	4	0	0	0	0	0	0	1	0	2	2	4	2	3	3	1	22
C80 Unknown primary	4	0	0	0	2	0	1	2	8	25	31	46	66	92	60	57	53	447
C81 Hodgkin disease	1	0	2	2	8	13	9	1	2	3	9	5	7	7	2	4	1	76
C82 Follicular (nodular) non-Hodgkin lymphoma	0	0	0	0	0	1	2	2	1	4	5	11	7	3	1	5	1	43

ICD 10 code and site	Age Groups																	Total
	Not kn	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C83 Diffuse non-Hodgkin lymphoma	0	3	3	3	2	5	7	4	3	4	7	12	13	12	10	12	8	108
C84 Peripheral and cutaneous T-cell lymphoma	0	1	1	1	3	1	1	0	0	0	3	5	2	2	1	4	3	28
C85 Other and unspecified types of non-Hodgkin lymphoma	1	1	0	0	3	6	8	8	3	6	11	25	25	23	22	20	20	182
C90 Multiple myeloma and malignant plasma cell neoplasms	0	0	0	0	0	0	0	3	4	6	7	14	20	35	31	17	24	161
C91 Lymphoid leukaemia	0	36	24	18	16	7	9	10	5	5	3	2	13	10	6	6	6	176
C92 Myeloid leukaemia	0	1	4	3	5	7	8	10	7	8	17	21	14	25	13	13	15	171
C93 Monocytic leukaemia	0	0	0	1	0	0	1	0	1	0	0	0	0	1	1	0	2	7
C94 Other leukaemia of specified cell type	0	0	1	0	0	0	1	0	0	0	2	0	3	1	0	1	1	10
C95 Leukaemia of unspecified cell type	0	0	0	1	0	0	0	0	0	1	1	0	1	1	3	1	1	10
C96 Other unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue	0	3	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
D45 Polycythemia vera	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	2
D46 Myelodysplastic syndromes	0	1	0	0	0	0	0	0	1	0	1	5	2	4	3	2	3	22
D47 Other neoplasms of uncertain behavior of lymphoid, haematopoietic and related tissue	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2
Total	21	98	66	47	78	105	108	138	182	312	612	1,014	1,152	1,471	1,088	897	981	8,370

Table 12: Cancer cases by age group - Female 2011

ICD 10 code and site	Age Groups																	Total
	Not kn	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C00 Lip	0	0	0	0	0	0	0	0	1	0	1	0	3	2	5	5	4	21
C01 Base of tongue	0	0	0	0	0	0	1	1	1	0	1	3	1	5	1	2	1	17
C02 Other and unspecified parts of tongue	0	0	0	0	1	0	1	3	4	3	8	14	19	20	9	11	15	108
C03 Gum	0	0	0	0	0	0	0	0	1	1	0	4	3	8	7	9	7	40
C04 Floor of mouth	0	0	0	0	0	0	0	0	1	1	4	4	5	5	0	3	3	26
C05 Palate	0	0	0	0	0	2	2	0	0	1	0	3	2	7	4	4	3	28
C06 Other and unspecified parts of mouth	3	0	0	0	1	0	0	3	2	2	9	12	15	29	24	33	44	177
C07 Parotid gland	0	0	0	2	1	1	2	2	4	2	4	3	3	6	2	1	5	38
C08 Other and unspecified major salivary gland	0	0	0	0	1	0	0	1	1	1	0	1	1	0	1	1	1	9
C09 Tonsil	0	0	0	0	0	0	0	0	0	1	0	1	2	2	0	1	1	8
C10 Oropharynx	0	0	0	0	0	0	0	0	0	0	0	1	1	4	1	1	0	8
C11 Nasopharynx	0	0	0	1	0	0	0	0	0	5	1	1	1	1	3	1	1	15
C12 Pyriform sinus	0	0	0	0	0	0	0	0	0	0	0	0	2	3	4	2	1	12
C13 Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	4	2	7	1	1	5	20
C14 Other and ill-defined sites in the lip, oral cavity and pharynx	0	0	0	0	1	0	0	0	0	2	2	1	1	1	2	3	0	13
C15 Oesophagus	1	0	0	0	0	0	0	1	9	12	29	45	80	96	106	64	75	518
C16 Stomach	0	0	0	0	0	1	0	2	5	3	8	14	18	14	19	14	14	112
C17 Small intestine	0	0	0	0	0	0	0	0	2	2	5	2	0	3	0	4	3	21
C18 Colon	0	0	0	0	1	3	3	7	13	21	31	34	35	50	34	26	25	283
C19 Rectosigmoid junction	0	0	0	0	0	0	0	0	0	3	3	4	12	8	10	3	3	46
C20 Rectum	0	0	0	0	0	2	5	9	6	15	12	33	30	44	32	33	41	262
C21 Anus and anal canal	0	0	0	0	0	0	0	0	1	0	2	1	4	2	6	9	5	30
C22 Liver and intrahepatic bile ducts	1	8	2	0	0	0	1	0	1	1	3	1	8	9	5	5	6	51
C23 Gallbladder	0	0	0	0	0	0	1	0	1	1	4	4	5	3	2	6	1	28
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	0	1	1	0	2	6	2	4	7	4	4	4	35
C25 Pancreas	0	0	0	0	0	0	1	1	3	0	5	6	10	8	9	5	4	52
C26 Other and ill-defined digestive organs	0	0	0	0	1	0	0	0	0	2	0	2	1	0	1	3	1	11
C30 Nasal cavity and middle ear	0	0	0	0	0	0	0	0	0	5	1	3	2	1	3	2	0	17
C31 Accessory sinuses	0	0	0	0	0	0	0	2	0	0	1	2	1	2	0	0	2	10
C32 Larynx	0	0	0	0	0	0	0	1	1	2	3	11	3	10	3	4	9	47
C33 Trachea	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
C34 Bronchus and lung	1	1	0	0	0	0	5	6	11	14	13	27	24	27	23	16	21	189
C37 Thymus	0	0	0	0	0	0	2	0	2	0	1	0	1	1	0	0	0	7
C38 Heart, mediastinum and pleura	0	1	0	1	0	0	2	0	0	0	0	1	0	0	1	0	1	7
C40 Bone and articular cartilage of limbs	0	2	1	6	7	1	2	1	2	2	0	1	1	0	0	0	0	26

ICD 10 code and site	Age Groups																	Total
	Not kn	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C41 Bone and articular cartilage of other and unspecified sites	0	0	0	1	3	0	5	1	1	0	2	2	2	2	2	0	0	21
C43 Melanoma of skin	0	0	0	0	0	0	2	1	1	2	4	4	5	4	2	2	5	32
C44 Other malignant neoplasms of skin	0	0	0	0	1	1	1	3	4	2	4	11	6	13	11	8	22	87
C45 Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2
C47 Peripheral nerves and autonomic nervous system	1	0	0	0	0	0	0	0	1	1	1	1	0	1	0	2	1	9
C48 Retroperitoneum and peritoneum	0	1	1	0	0	2	0	0	0	0	0	2	4	1	0	1	0	12
C49 Connective, subcutaneous and other soft tissues	0	6	1	4	6	3	4	7	3	4	5	4	7	9	3	1	5	72
C50 Breast	3	0	0	0	0	4	20	72	130	281	338	374	378	371	208	124	116	2,419
C51 Vulva	0	0	0	0	0	0	0	0	0	0	1	2	6	3	1	7	8	28
C52 Vagina	0	0	0	0	0	0	0	0	1	1	1	2	0	4	2	4	7	22
C53 Cervix uteri	2	0	0	0	0	2	2	10	32	61	99	113	144	125	111	63	75	839
C54 Corpus uteri	1	0	0	0	0	1	2	0	6	15	29	58	77	67	55	36	20	367
C55 Uterus not specified	0	0	0	0	0	0	1	1	2	5	3	7	6	7	4	4	4	44
C56 Ovary	0	0	2	6	16	14	12	17	33	43	81	88	106	106	83	43	31	681
C57 Other and unspecified female genital organs	0	0	0	0	0	0	0	0	0	0	2	1	0	2	1	0	0	6
C58 Placenta	0	0	0	0	0	0	2	8	0	2	1	0	0	0	0	0	0	13
C64 Kidney	0	10	1	1	0	2	0	0	4	4	4	7	8	7	2	4	4	58
C65 Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
C66 Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C67 Bladder	0	0	0	0	0	1	0	3	0	0	3	5	8	13	10	8	13	64
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
C69 Eye and adnexa	0	12	1	0	0	0	0	0	0	0	0	1	0	1	1	0	1	17
C70 Meninges	0	0	0	0	0	0	0	2	0	4	0	0	2	1	0	0	0	9
C71 Brain	0	10	9	4	4	3	2	7	8	9	12	12	14	11	8	3	7	123
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	0	2	0	0	0	0	0	0	1	3	0	0	0	0	0	6
C73 Thyroid gland	0	0	1	5	11	51	68	96	102	87	65	69	71	56	35	25	18	760
C74 Adrenal gland	0	8	0	1	0	1	2	0	0	0	1	1	1	1	0	0	0	16
C75 Other endocrine glands and related structures	0	1	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	4
C76 Other and ill-defined sites	0	4	0	0	0	0	0	1	0	0	3	2	6	1	3	0	1	21
C80 Unknown primary	4	0	0	0	1	1	5	7	6	7	27	26	38	52	37	27	29	267
C81 Hodgkin disease	0	0	1	3	2	12	8	4	2	2	0	1	2	3	3	0	2	45
C82 Follicular (nodular) non-Hodgkin lymphoma	0	0	0	0	0	0	3	1	1	2	5	1	2	1	4	2	7	29
C83 Diffuse non-Hodgkin lymphoma	0	1	1	1	2	0	2	4	4	4	5	11	12	6	9	6	4	72
C84 Peripheral and cutaneous T-cell lymphoma	0	1	0	1	0	0	1	0	0	1	0	0	1	2	3	3	3	16

ICD 10 code and site	Age Groups																	Total
	Not kn	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C85 Other and unspecified types of non-Hodgkin lymphoma	1	0	0	2	6	5	2	3	8	5	5	21	19	18	14	13	17	139
C90 Multiple myeloma and malignant plasma cell neoplasms	0	0	0	0	0	0	0	1	2	3	10	18	17	35	28	32	21	167
C91 Lymphoid leukaemia	0	31	23	13	6	1	2	1	2	3	1	2	3	5	2	5	6	106
C92 Myeloid leukaemia	1	5	3	5	4	7	12	10	12	13	16	15	15	18	16	22	13	187
C93 Monocytic leukaemia	0	3	0	0	0	0	0	0	0	1	0	2	0	1	0	0	0	7
C94 Other leukaemia of specified cell type	0	2	0	0	0	0	0	0	0	1	1	1	1	1	3	1	0	11
C95 Leukaemia of unspecified cell type	2	0	2	0	0	0	1	1	0	0	0	1	0	0	1	3	1	12
C96 Other unspecified malignant neoplasms of lymphoid,haematopoietic and related tissue	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
D45 Polycythemia vera	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	4
D46 Myelodysplastic syndromes	0	0	0	0	0	0	1	1	2	0	0	1	4	3	1	0	3	16
D47 Other neoplasms of uncertain behaviour of lymphoid,haematopoietic and related tissue	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	0	3
Total	21	110	49	59	78	121	189	303	439	668	888	1,114	1,269	1,338	989	726	751	9,112

Table 13: Cancer cases by ethnicity, sex and sub-site - 2011

ICD 10 code and site		Sinhala		Tamil		Muslim		Other		Unknown		Total	
		Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C00	Lip	71	11	7	6	3	1	0	0	3	3	84	21
C01	Base of tongue	126	12	8	2	4	1	0	2	2	0	140	17
C02	Other and unspecified parts of tongue	307	74	33	22	7	8	5	1	13	3	365	108
C03	Gum	78	25	17	11	7	4	1	0	1	0	104	40
C04	Floor of mouth	103	18	16	7	4	1	0	0	4	0	127	26
C05	Palate	133	20	12	6	6	0	4	0	4	2	159	28
C06	Other and unspecified parts of mouth	451	103	70	49	12	13	4	0	8	11	545	176
C07	Parotid gland	23	28	4	8	1	1	0	0	0	1	28	38
C08	Other and unspecified major salivary gland	8	6	0	2	1	1	0	0	0	0	9	9
C09	Tonsil	120	6	5	2	6	0	3	0	2	0	136	8
C10	Oropharynx	98	4	9	2	3	1	0	0	2	1	112	8
C11	Nasopharynx	18	12	6	1	5	1	0	0	0	1	29	15
C12	Pyramidal sinus	119	9	18	2	11	0	1	1	4	0	153	12
C13	Hypopharynx	36	17	4	2	1	0	0	1	2	0	43	20
C14	Other and ill-defined sites in the lip, oral cavity and pharynx	55	7	8	5	2	0	2	0	1	1	68	13
C15	Oesophagus	482	366	89	127	21	12	2	6	14	7	608	518
C16	Stomach	214	83	50	19	14	7	2	1	5	2	285	112
C17	Small intestine	15	16	1	3	0	1	0	0	1	1	17	21
C18	Colon	186	228	21	28	15	12	3	4	3	11	228	283
C19	Rectosigmoid junction	35	42	1	2	4	1	0	1	1	0	41	46
C20	Rectum	211	223	15	14	10	15	10	2	8	8	254	262
C21	Anus and anal canal	35	22	7	4	2	1	2	1	2	2	48	30
C22	Liver and intrahepatic bile ducts	120	37	8	5	7	5	3	1	4	3	142	51
C23	Gallbladder	7	19	2	4	0	3	0	0	0	2	9	28
C24	Other and unspecified parts of biliary tract	28	31	4	1	3	2	0	0	0	1	35	35
C25	Pancreas	42	42	4	7	3	1	1	1	1	1	51	52
C26	Other and ill-defined digestive organs	7	11	0	0	1	0	0	0	0	0	8	11
C30	Nasal cavity and middle ear	21	13	0	2	1	2	0	0	3	0	25	17
C31	Accessory sinuses	18	9	2	1	1	0	0	0	0	0	21	10
C32	Larynx	383	32	39	9	18	3	9	3	5	0	454	47
C33	Trachea	4	1	0	0	0	0	0	0	0	0	4	1
C34	Bronchus and lung	641	151	47	14	68	13	13	7	15	4	784	189
C37	Thymus	10	6	0	0	0	1	0	0	0	0	10	7
C38	Heart, mediastinum and pleura	15	7	0	0	2	0	0	0	0	0	17	7
C39	Other and ill-defined sites intrathoracic organs	1	0	0	0	0	0	0	0	0	0	1	0
C40	Bone and articular cartilage of limbs	27	21	4	2	3	3	0	0	1	0	35	26

ICD 10 code and site	Sinhala		Tamil		Muslim		Other		Unknown		Total	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C41 Bone and articular cartilage of other and unspecified sites	19	16	3	2	0	2	0	1	3	0	25	21
C43 Melanoma of skin	25	21	2	6	1	2	0	2	0	1	28	32
C44 Other malignant neoplasms of skin	125	75	12	8	7	3	2	0	3	1	149	87
C45 Mesothelioma	3	1	2	1	0	0	0	0	1	0	6	2
C47 Peripheral nerves and autonomic nervous system	11	5	2	3	0	1	0	0	1	0	14	9
C48 Retroperitoneum and peritoneum	11	10	0	1	0	1	0	0	0	0	11	12
C49 Connective, subcutaneous and other soft tissues	62	57	8	9	7	5	0	0	0	1	77	72
C50 Breast	39	1,940	5	225	5	203	0	27	1	24	50	2,419
C51 Vulva		22		4		1		1		0		28
C52 Vagina		19		3		0		0		0		22
C53 Cervix uteri		635		138		43		6		17		839
C54 Corpus uteri		283		45		25		7		7		367
C55 Uterus not specified		34		5		4		0		1		44
C56 Ovary		549		73		43		9		7		681
C57 Other and unspecified female genital organs		5		0		0		1		0		6
C58 Placenta		9		3		1		0		0		13
C60 Penis	56		13		1		0		0		70	
C61 Prostate gland	389		45		29		6		11		480	
C62 Testis	51		5		4		1		0		61	
C63 Other and unspecified male genital organs	3		0		0		0		0		3	
C64 Kidney	91	46	7	8	4	3	0	1	1	0	103	58
C65 Renal pelvis		1	0	0	0	0	0	0	0	0	0	1
C66 Ureter	2	1	0	0	0	0	0	0	0	0	2	1
C67 Bladder	207	56	13	4	16	2	2	2	5	0	243	64
C68 Other and unspecified urinary organs	2	1	1	0	0	0	0	0	0	0	3	1
C69 Eye and adnexa	23	17	0	0	0	0	0	0	0	0	23	17
C70 Meninges	6	8	0	0	0	1	0	0	0	0	6	9
C71 Brain	141	94	17	14	11	10	1	3	2	2	172	123
C72 Spinal cord, cranial nerves and other parts of central nervous system	3	6	0	0	0	0	0	0	0	0	3	6
C73 Thyroid gland	143	625	14	56	6	52	1	20	3	5	167	758
C74 Adrenal gland	16	12	2	1	1	3	0	0	1	0	20	16
C75 Other endocrine glands and related structures	3	4	0	0	0	0	0	0	0	0	3	4
C76 Other and ill-defined sites	19	18	2	0	1	3	0	0	0	0	22	21
C80 Unknown primary	362	210	38	34	27	14	8	5	12	4	447	267

ICD 10 code and site	Sinhala		Tamil		Muslim		Other		Unknown		Total	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C81 Hodgkin disease	58	37	8	3	7	5	2	0	1	0	76	45
C82 Follicular (nodular) non-Hodgkin lymphoma	37	26	4	2	2	1	0	0	0	0	43	29
C83 Diffuse non-Hodgkin lymphoma	95	61	6	5	7	5	0	1	0	0	108	72
C84 Peripheral and cutaneous T-cell lymphoma	23	11	4	1	1	4	0	0	0	0	28	16
C85 Other and unspecified types of non-Hodgkin lymphoma	135	108	22	11	22	14	1	3	2	3	182	139
C90 Multiple myeloma and malignant plasma cell neoplasms	129	149	15	7	12	4	1	5	3	2	160	167
C91 Lymphoid leukaemia	148	92	13	9	13	4	1	0	0	0	175	105
C92 Myeloid leukaemia	142	136	15	27	11	19	2	3	1	2	171	187
C93 Monocytic leukaemia	6	6	1	1	0	0	0	0	0	0	7	7
C94 Other leukaemia of specified cell type	9	8	1	1	0	1	0	1	0	0	10	11
C95 Leukaemia of unspecified cell type	9	12	0	0	1	0	0	0	0	0	10	12
C96 Other unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	4	3	0	0	1	0	0	0	0	0	5	3
D45 Polycythemia vera	0	1	0	3	2	0	0	0	0	0	2	4
D46 Myelodysplastic syndromes	19	10	3	3	0	2	0	1	0	0	22	16
D47 Other neoplasms of uncertain behavior of lymphoid, haematopoietic and related tissue	1	2	1	0	0	1	0	0	0	0	2	3
Total	6,877	7,157	795	1,086	445	596	93	131	160	142	8,370	9,112

Table 14: Age Specific Rates by site - Male 2011

ICD 10 code and site		Age group															
		00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C00	Lip	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.3	0.3	2.9	2.8	4.4	5.2	4.0	8.8
C01	Base of tongue	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.3	1.7	3.0	4.8	4.5	8.1	5.6	8.6	3.9
C02	Other and unspecified parts of tongue	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.9	3.5	7.3	13.1	11.5	21.9	13.8	18.3	17.2
C03	Gum	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	1.0	2.5	3.3	5.1	9.9	8.0	7.4
C04	Floor of mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.8	2.6	3.6	6.0	8.1	5.6	5.1	5.9
C05	Palate	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.8	1.8	4.8	6.3	10.8	7.3	10.9	8.3
C06	Other and unspecified parts of mouth	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.8	2.2	6.9	9.7	22.6	32.3	30.2	39.4	46.6
C07	Parotid gland	0.0	0.0	0.0	0.1	0.4	0.0	0.1	0.5	0.0	0.2	0.5	1.0	0.7	1.3	2.3	0.0
C08	Other and unspecified major salivary gland	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.9	1.1	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.0	2.7	4.8	6.3	9.4	3.9	5.1	5.4
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	1.6	4.8	3.8	7.7	5.2	6.9	3.9
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.1	0.1	0.5	0.4	1.3	1.3	2.6	0.6	0.5
C12	Pyriform sinus	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.7	2.9	3.1	5.8	7.4	11.6	11.4	9.3
C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.6	1.1	1.0	2.7	3.9	2.9	2.0
C14	Other and ill-defined sites in the lip, oral cavity and pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	1.3	1.6	2.5	4.7	3.4	2.9	5.9
C15	Oesophagus	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.9	1.8	8.0	16.5	27.6	39.1	39.2	36.0	31.9
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.4	1.4	3.8	8.6	10.5	21.9	15.1	14.9	13.7
C17	Small intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.2	0.3	0.7	1.3	2.9	0.0
C18	Colon	0.0	0.0	0.0	0.0	0.2	0.1	1.0	1.2	1.7	2.4	5.4	8.8	13.5	13.8	8.0	14.2
C19	Rectosigmoid junction	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.5	0.9	0.8	4.4	1.7	2.3	2.5
C20	Rectum	0.0	0.0	0.0	0.0	0.1	0.1	0.8	1.0	0.8	2.2	4.1	9.5	17.8	13.8	19.4	18.6
C21	Anus and anal canal	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.3	1.4	1.0	3.4	4.7	1.7	2.5
C22	Liver and intrahepatic bile ducts	0.3	0.2	0.1	0.2	0.0	0.1	0.3	0.8	0.7	2.1	2.0	3.8	8.8	7.8	11.4	6.9
C23	Gallbladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.2	0.5	0.3	0.0	0.6	0.0
C24	Other and unspecified parts of biliary tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	1.8	0.8	2.7	1.7	2.3	0.5
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.8	0.2	2.8	4.4	2.6	2.9	2.0
C26	Other and ill-defined digestive organs	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.7	0.4	0.0	0.5
C30	Nasal cavity and middle ear	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.5	0.4	0.8	1.3	1.7	1.1	2.0
C31	Accessory sinuses	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.2	0.4	0.8	1.3	0.4	2.3	1.0
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	1.8	5.9	12.4	21.3	27.3	25.9	33.1	22.1
C33	Trachea	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.3	0.0	0.0	0.0
C34	Bronchus and lung	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.5	3.6	5.6	17.6	32.3	62.0	58.2	48.0	41.2
C37	Thymus	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.2	0.0	0.7	0.4	1.1	0.0

ICD 10 code and site		Age group															
		00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C38	Heart, mediastinum and pleura	0.1	0.0	0.0	0.1	0.4	0.4	0.0	0.3	0.1	0.0	0.2	0.3	0.7	0.0	0.6	0.0
C39	Other and ill-defined sites in the respiratory system and intrathoracic organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40	Bone and articular cartilage of limbs	0.0	0.1	0.4	1.0	0.5	0.2	0.0	0.3	0.4	0.2	0.5	0.8	0.0	0.0	0.6	0.0
C41	Bone and articular cartilage of other and unspecified sites	0.0	0.0	0.1	0.1	0.4	0.4	0.1	0.3	0.0	0.6	0.4	0.5	0.7	0.0	0.0	1.0
C43	Melanoma of skin	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.2	0.5	0.8	1.0	2.6	4.0	1.0
C44	Other malignant neoplasms of skin	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.4	1.0	2.2	3.1	5.3	7.1	10.3	8.6	11.3
C45	Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.7	0.4	0.0	0.0
C47	Peripheral nerves and autonomic nervous system	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.1	0.3	0.2	0.2	0.5	0.7	0.0	0.6	0.0
C48	Retroperitoneum and peritoneum	0.2	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.7	0.4	0.0	0.5
C49	Connective, subcutaneous and other soft tissues	0.2	0.2	0.2	0.1	0.6	0.2	0.6	0.4	0.7	1.3	1.4	0.5	1.7	4.7	4.6	2.9
C50	Breast	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.6	1.1	0.8	3.4	3.0	4.0	3.4
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	1.3	1.6	3.0	4.0	4.3	4.0	3.9
C61	Prostate gland	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.3	2.2	9.8	26.3	42.7	58.9	70.6
C62	Testis	0.4	0.0	0.1	1.0	0.9	1.4	0.9	0.9	0.4	0.3	0.7	0.0	0.3	0.4	0.6	0.0
C63	Other and unspecified male genital organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.5
C64	Kidney	0.4	0.5	0.0	0.0	0.1	0.0	0.6	0.5	0.6	0.8	2.3	2.8	6.7	8.2	2.3	3.9
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0
C67	Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.3	1.1	3.8	8.0	19.5	18.1	16.0	24.5
C68	Other and unspecified urinary organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0
C69	Eye and adnexa	1.3	0.3	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.8	0.0	0.0	0.6	0.5
C70	Meninges	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.3	0.7	0.0	0.0	0.5
C71	Brain	0.6	1.2	0.4	0.6	0.8	1.4	1.3	1.4	2.1	2.7	3.8	4.0	4.7	4.7	5.1	1.5
C72	Spinal cord, cranial nerves and other parts of central nervous system	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.3	0.0	0.0	0.0
C73	Thyroid gland	0.1	0.2	0.2	0.2	1.1	1.1	2.7	3.0	1.7	2.7	2.0	5.8	6.1	2.2	4.0	1.5
C74	Adrenal gland	1.3	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.2	0.3	0.3	0.0	0.0	0.0
C75	Other endocrine glands and related structures	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5

ICD 10 code and site	Age group															
	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C76 Other and ill-defined sites	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.4	1.0	0.7	1.3	1.7	0.5
C80 Unknown primary	0.0	0.0	0.0	0.2	0.0	0.1	0.3	1.0	3.5	4.9	8.3	16.5	31.0	25.9	32.6	26.0
C81 Hodgkin disease	0.0	0.2	0.2	0.8	1.3	1.1	0.1	0.3	0.4	1.4	0.9	1.8	2.4	0.9	2.3	0.5
C82 Follicular (nodular) non-Hodgkin lymphoma	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.1	0.6	0.8	2.0	1.8	1.0	0.4	2.9	0.5
C83 Diffuse non-Hodgkin lymphoma	0.3	0.3	0.3	0.2	0.5	0.9	0.5	0.4	0.6	1.1	2.2	3.3	4.0	4.3	6.9	3.9
C84 Peripheral and cutaneous T-cell lymphoma	0.1	0.1	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.5	0.9	0.5	0.7	0.4	2.3	1.5
C85 Other and unspecified types of non-Hodgkin lymphoma	0.1	0.0	0.0	0.3	0.6	1.0	1.0	0.4	0.8	1.8	4.5	6.3	7.7	9.5	11.4	9.8
C90 Multiple myeloma and malignant plasma cell neoplasms	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.8	1.1	2.5	5.0	11.8	13.4	9.7	11.8
C91 Lymphoid leukaemia	4.0	2.6	1.9	1.6	0.7	1.1	1.3	0.7	0.7	0.5	0.4	3.3	3.4	2.6	3.4	2.9
C92 Myeloid leukaemia	0.1	0.4	0.3	0.5	0.7	1.0	1.3	0.9	1.1	2.7	3.8	3.5	8.4	5.6	7.4	7.4
C93 Monocytic leukaemia	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.4	0.0	1.0
C94 Other leukaemia of specified cell type	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.8	0.3	0.0	0.6	0.5
C95 Leukaemia of unspecified cell type	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.3	0.3	1.3	0.6	0.5
C96 Other unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
D45 Polycythemia vera	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0
D46 Myelodysplastic syndromes	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.9	0.5	1.3	1.3	1.1	1.5
D47 Other neoplasms of uncertain behavior of lymphoid, haematopoietic and related tissue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5

Table 15: Age Specific Rates by site - Female 2011

ICD 10 code and site	Age group															
	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C00 Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.7	0.6	1.9	2.5	1.7
C01 Base of tongue	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.2	0.5	0.2	1.6	0.4	1.0	0.4
C02 Other and unspecified parts of tongue	0.0	0.0	0.0	0.1	0.0	0.1	0.4	0.5	0.4	1.2	2.4	4.4	6.3	3.4	5.5	6.3
C03 Gum	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.7	0.7	2.5	2.6	4.5	2.9
C04 Floor of mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.6	0.7	1.2	1.6	0.0	1.5	1.3
C05 Palate	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.5	0.5	2.2	1.5	2.0	1.3
C06 Other and unspecified parts of mouth	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.3	0.3	1.4	2.1	3.5	9.2	9.0	16.5	18.4
C07 Parotid gland	0.0	0.0	0.2	0.1	0.1	0.2	0.2	0.5	0.3	0.6	0.5	0.7	1.9	0.7	0.5	2.1
C08 Other and unspecified major salivary gland	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.2	0.2	0.0	0.4	0.5	0.4
C09 Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.5	0.6	0.0	0.5	0.4
C10 Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.3	0.4	0.5	0.0
C11 Nasopharynx	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.2	0.2	0.3	1.1	0.5	0.4
C12 Pyriform sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.0	1.5	1.0	0.4
C13 Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.5	2.2	0.4	0.5	2.1
C14 Other and ill-defined sites in the lip, oral cavity and pharynx	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.3	0.2	0.2	0.3	0.7	1.5	0.0
C15 Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.1	1.7	4.5	7.8	18.6	30.5	39.6	32.0	31.4
C16 Stomach	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.6	0.4	1.2	2.4	4.2	4.4	7.1	7.0	5.9
C17 Small intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.8	0.3	0.0	1.0	0.0	2.0	1.3
C18 Colon	0.0	0.0	0.0	0.1	0.3	0.4	0.9	1.7	2.9	4.8	5.9	8.2	15.9	12.7	13.0	10.5
C19 Rectosigmoid junction	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.7	2.8	2.5	3.7	1.5	1.3
C20 Rectum	0.0	0.0	0.0	0.0	0.2	0.6	1.1	0.8	2.1	1.9	5.7	7.0	14.0	11.9	16.5	17.2
C21 Anus and anal canal	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.2	0.9	0.6	2.2	4.5	2.1
C22 Liver and intrahepatic bile ducts	0.9	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.5	0.2	1.9	2.9	1.9	2.5	2.5
C23 Gallbladder	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.6	0.7	1.2	1.0	0.7	3.0	0.4
C24 Other and unspecified parts of biliary tract	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.9	0.3	0.9	2.2	1.5	2.0	1.7
C25 Pancreas	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.0	0.8	1.0	2.3	2.5	3.4	2.5	1.7
C26 Other and ill-defined digestive organs	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.2	0.0	0.4	1.5	0.4
C30 Nasal cavity and middle ear	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.5	0.5	0.3	1.1	1.0	0.0
C31 Accessory sinuses	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.3	0.2	0.6	0.0	0.0	0.8
C32 Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.5	1.9	0.7	3.2	1.1	2.0	3.8
C33 Trachea	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
C34 Bronchus and lung	0.1	0.0	0.0	0.0	0.0	0.6	0.7	1.4	1.9	2.0	4.7	5.6	8.6	8.6	8.0	8.8
C37 Thymus	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.2	0.0	0.2	0.3	0.0	0.0	0.0
C38 Heart, mediastinum and pleura	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.0	0.4
C40 Bone and articular cartilage of limbs	0.2	0.1	0.6	0.7	0.1	0.2	0.1	0.3	0.3	0.0	0.2	0.2	0.0	0.0	0.0	0.0

ICD 10 code and site	Age group															
	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C41 Bone and articular cartilage of other and unspecified sites	0.0	0.0	0.1	0.3	0.0	0.6	0.1	0.1	0.0	0.3	0.3	0.5	0.6	0.7	0.0	0.0
C43 Melanoma of skin	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.3	0.6	0.7	1.2	1.3	0.7	1.0	2.1
C44 Other malignant neoplasms of skin	0.0	0.0	0.0	0.1	0.1	0.1	0.4	0.5	0.3	0.6	1.9	1.4	4.1	4.1	4.0	9.2
C45 Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0
C47 Peripheral nerves and autonomic nervous system	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.0	0.3	0.0	1.0	0.4
C48 Retroperitoneum and peritoneum	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.9	0.3	0.0	0.5	0.0
C49 Connective, subcutaneous and other soft tissues	0.7	0.1	0.4	0.6	0.3	0.5	0.9	0.4	0.6	0.8	0.7	1.6	2.9	1.1	0.5	2.1
C50 Breast	0.0	0.0	0.0	0.0	0.4	2.4	8.9	16.6	38.7	52.5	65.2	88.1	117.8	77.6	62.0	48.5
C51 Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	1.4	1.0	0.4	3.5	3.3
C52 Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.0	1.3	0.7	2.0	2.9
C53 Cervix uteri	0.0	0.0	0.0	0.0	0.2	0.2	1.2	4.1	8.4	15.4	19.7	33.6	39.7	41.4	31.5	31.4
C54 Corpus uteri	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.8	2.1	4.5	10.1	17.9	21.3	20.5	18.0	8.4
C55 Uterus not specified	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.7	0.5	1.2	1.4	2.2	1.5	2.0	1.7
C56 Ovary	0.0	0.2	0.6	1.6	1.4	1.4	2.1	4.2	5.9	12.6	15.3	24.7	33.7	31.0	21.5	13.0
C57 Other and unspecified female genital organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.6	0.4	0.0	0.0
C58 Placenta	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0
C64 Kidney	1.1	0.1	0.1	0.0	0.2	0.0	0.0	0.5	0.6	0.6	1.2	1.9	2.2	0.7	2.0	1.7
C65 Renal pelvis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
C66 Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0
C67 Bladder	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.5	0.9	1.9	4.1	3.7	4.0	5.4
C68 Other and unspecified urinary organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
C69 Eye and adnexa	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.4	0.0	0.4
C70 Meninges	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.0	0.5	0.3	0.0	0.0	0.0
C71 Brain	1.1	1.0	0.4	0.4	0.3	0.2	0.9	1.0	1.2	1.9	2.1	3.3	3.5	3.0	1.5	2.9
C72 Spinal cord, cranial nerves and other parts of central nervous system	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.0
C73 Thyroid gland	0.0	0.1	0.5	1.1	5.2	8.1	11.9	13.0	12.0	10.1	12.0	16.6	17.8	13.1	12.5	7.5
C74 Adrenal gland	0.9	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.2	0.2	0.2	0.3	0.0	0.0	0.0
C75 Other endocrine glands and related structures	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0
C76 Other and ill-defined sites	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.3	1.4	0.3	1.1	0.0	0.4
C80 Unknown primary	0.0	0.0	0.0	0.1	0.1	0.6	0.9	0.8	1.0	4.2	4.5	8.9	16.5	13.8	13.5	12.1
C81 Hodgkin disease	0.0	0.1	0.3	0.2	1.2	1.0	0.5	0.3	0.3	0.0	0.2	0.5	1.0	1.1	0.0	0.8
C82 Follicular (nodular) non-Hodgkin lymphoma	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.1	0.3	0.8	0.2	0.5	0.3	1.5	1.0	2.9
C83 Diffuse non-Hodgkin lymphoma	0.1	0.1	0.1	0.2	0.0	0.2	0.5	0.5	0.6	0.8	1.9	2.8	1.9	3.4	3.0	1.7

ICD 10 code and site	Age group															
	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C84 Peripheral and cutaneous T-cell lymphoma	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.2	0.6	1.1	1.5	1.3
C85 Other and unspecified types of non-Hodgkin lymphoma	0.0	0.0	0.2	0.6	0.5	0.2	0.4	1.0	0.7	0.8	3.7	4.4	5.7	5.2	6.5	7.1
C90 Multiple myeloma and malignant plasma cell neoplasms	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.4	1.6	3.1	4.0	11.1	10.4	16.0	8.8
C91 Lymphoid leukaemia	3.6	2.6	1.4	0.6	0.1	0.2	0.1	0.3	0.4	0.2	0.3	0.7	1.6	0.7	2.5	2.5
C92 Myeloid leukaemia	0.6	0.3	0.5	0.4	0.7	1.4	1.2	1.5	1.8	2.5	2.6	3.5	5.7	6.0	11.0	5.4
C93 Monocytic leukaemia	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.3	0.0	0.0	0.0
C94 Other leukaemia of specified cell type	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.2	0.3	1.1	0.5	0.0
C95 Leukaemia of unspecified cell type	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.4	1.5	0.4
C96 Other unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
D45 Polycythemia vera	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.0	0.4
D46 Myelodysplastic syndromes	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.0	0.0	0.2	0.9	1.0	0.4	0.0	1.3
D47 Other neoplasms of uncertain behavior of lymphoid, haematopoietic and related tissue	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5	0.0

Table 16: Lip, tongue and mouth - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	1,524	18.2	16.4	1.99
Female	417	4.6	4.1	0.51
Total	1,941	11.1	10	1.22

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C00.0 External upper lip	6	3	9
C00.1 External lower lip	21	8	29
C00.2 External lip, NOS	4	0	4
C00.3 Mucosa of upper lip	2	0	2
C00.4 Mucosa of lower lip	4	3	7
C00.6 Commissure of lip	34	3	37
C00.8 Overlapping lesion of lip	3	0	3
C00.9 Lip, NOS	10	4	14
C01.9 Base of tongue, NOS	140	17	157
C02.0 Dorsal surface of tongue, NOS	9	2	11
C02.1 Border of tongue	47	18	65
C02.2 Ventral surface of tongue, NOS	4	0	4
C02.3 Anterior 2/3 of tongue, NOS	12	4	16
C02.4 Lingual tonsil	1	0	1
C02.8 Overlapping lesion of tongue	8	0	8
C02.9 Tongue, NOS	284	84	368
C03.0 Upper gum	28	10	38
C03.1 Lower gum	48	21	69
C03.9 Gum, NOS	28	9	37
C04.0 Anterior floor of mouth	2	1	3
C04.1 Lateral floor of mouth	1	0	1
C04.8 Overlapping lesion of floor of mouth	2	2	4
C04.9 Floor of mouth, NOS	122	23	145
C05.0 Hard palate	19	11	30
C05.1 Soft palate, NOS	68	6	74
C05.2 Uvula	7	0	7
C05.8 Overlapping lesion of palate	16	2	18
C05.9 Palate, NOS	49	9	58
C06.0 Cheek mucosa	299	99	398
C06.1 Vestibule of mouth	7	0	7
C06.2 Retromolar area	52	14	66
C06.8 Overlapping lesion of other/unspec. parts of mouth	12	4	16
C06.9 Mouth, NOS	175	60	235
Total	1,524	417	1,941

ICD O code and histology		Male	Female	Total
8000	Neoplasm, malignant	70	18	88
8010	Carcinoma, NOS	16	12	28
8022	Pleomorphic carcinoma	1	0	1
8032	Spindle cell carcinoma, NOS	2	0	2
8050	Papillary carcinoma, NOS	1	0	1
8051	Verrucous carcinoma, NOS	29	5	34
8070	Squamous cell carcinoma, NOS	1,366	349	1,715
8071	Squamous cell carcinoma, keratinizing, NOS	4	5	9
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	4	1	5
8082	Lymphoepithelial carcinoma	1	0	1
8083	Basaloid squamous cell carcinoma	9	2	11
8140	Adenocarcinoma, NOS	5	0	5
8200	Adenoid cystic carcinoma	2	8	10
8260	Papillary adenocarcinoma, NOS	0	1	1
8310	Clear cell adenocarcinoma, NOS	1	1	2
8430	Mucoepidermoid carcinoma	6	10	16
8480	Mucinous adenocarcinoma	0	1	1
8560	Adenosquamous carcinoma	0	1	1
8720	Malignant melanoma, NOS (except juvenile melanoma)	3	2	5
8800	Sarcoma, NOS	1	0	1
8815	Solitary fibrous tumour, malignant	1	0	1
8890	Leiomyosarcoma, NOS	1	0	1
8910	Embryonal rhabdomyosarcoma, NOS	1	0	1
9133	Epithelioid haemangioendothelioma, malignant	0	1	1
Total		1,524	417	1,941




Figure 18: Age specific rates - Lip, tongue and mouth




Figure 19: ASR, 2006-2011, Lip, tongue and mouth

Table 17: Lip, tongue, mouth and pharynx - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	2,065	24.7	22.3	2.71
Female	493	5.4	4.9	0.61
Total	2,558	14.6	13.2	1.61

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C00.0 External upper lip	6	3	9
C00.1 External lower lip	21	8	29
C00.2 External lip, NOS	4	0	4
C00.3 Mucosa of upper lip	2	0	2
C00.4 Mucosa of lower lip	4	3	7
C00.6 Commissure of lip	34	3	37
C00.8 Overlapping lesion of lip	3	0	3
C00.9 Lip, NOS	10	4	14
C01.9 Base of tongue, NOS	140	17	157
C02.0 Dorsal surface of tongue, NOS	9	2	11
C02.1 Border of tongue	47	18	65
C02.2 Ventral surface of tongue, NOS	4	0	4
C02.3 Anterior 2/3 of tongue, NOS	12	4	16
C02.4 Lingual tonsil	1	0	1
C02.8 Overlapping lesion of tongue	8	0	8
C02.9 Tongue, NOS	284	84	368
C03.0 Upper gum	28	10	38
C03.1 Lower gum	48	21	69
C03.9 Gum, NOS	28	9	37
C04.0 Anterior floor of mouth	2	1	3
C04.1 Lateral floor of mouth	1	0	1
C04.8 Overlapping lesion of floor of mouth	2	2	4
C04.9 Floor of mouth, NOS	122	23	145
C05.0 Hard palate	19	11	30
C05.1 Soft palate, NOS	68	6	74
C05.2 Uvula	7	0	7
C05.8 Overlapping lesion of palate	16	2	18
C05.9 Palate, NOS	49	9	58
C06.0 Cheek mucosa	299	99	398
C06.1 Vestibule of mouth	7	0	7
C06.2 Retromolar area	52	14	66
C06.8 Overlapping lesion of other/unspec. parts of mouth	12	4	16
C06.9 Mouth, NOS	175	60	235
C09.0 Tonsillar fossa	15	0	15
C09.1 Tonsillar pillar	6	0	6
C09.8 Overlapping lesion of tonsil	6	1	7
C09.9 Tonsil, NOS	109	7	116
C10.0 Vallecula	78	5	83
C10.3 Posterior wall of oropharynx	1	0	1

ICD 10 code and site		Male	Female	Total
C10.4	Branchial cleft	1	0	1
C10.8	Overlapping lesion of oropharynx	3	2	5
C10.9	Oropharynx, NOS	29	1	30
C11.1	Posterior wall of nasopharynx	0	2	2
C11.9	Nasopharynx, NOS	29	13	42
C12.9	Pyramidal sinus	153	12	165
C13.0	Postcricoid region	26	16	42
C13.1	Aryepiglottic fold	15	1	16
C13.2	Posterior wall of hypopharynx	1	0	1
C13.9	Laryngopharynx, hypopharynx NOS	1	3	4
C14.0	Pharynx, NOS	65	13	78
C14.8	Overlapping lesion of lip, oral cavity, pharynx	3	0	3
Total		2,065	493	2,558

ICD O code and histology		Male	Female	Total
8000	Neoplasm, malignant	106	26	132
8010	Carcinoma, NOS	26	13	39
8041	Small cell carcinoma, NOS	1	1	2
8022	Pleomorphic carcinoma	1	0	1
8032	Spindle cell carcinoma, NOS	2	0	2
8050	Papillary carcinoma, NOS	1	0	1
8051	Verrucous carcinoma, NOS	29	5	34
8070	Squamous cell carcinoma, NOS	1,841	411	2,252
8071	Squamous cell carcinoma, keratinizing, NOS	8	6	14
8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	15	3	18
8082	Lymphoepithelial carcinoma	1	0	1
8083	Basaloid squamous cell carcinoma	10	2	12
8140	Adenocarcinoma, NOS	7	0	7
8200	Adenoid cystic carcinoma	2	8	10
8260	Papillary adenocarcinoma, NOS	0	1	1
8310	Clear cell adenocarcinoma, NOS	1	1	2
8430	Mucoepidermoid carcinoma	7	10	17
8480	Mucinous adenocarcinoma	0	1	1
8560	Adenosquamous carcinoma	0	1	1
8720	Malignant melanoma, NOS (except juvenile melanoma)	3	2	5
8800	Sarcoma, NOS	1	0	1
8815	Solitary fibrous tumor, malignant	1	0	1
8890	Leiomyosarcoma, NOS	1	0	1
8910	Embryonal rhabdomyosarcoma, NOS	1	1	2
9133	Epithelioid hemangioendothelioma, malignant	0	1	1
Total		2,065	493	2,558




Figure 20: Age specific rates - Lip, tongue, mouth and pharynx




Figure 21: ASR, 2006-2011, Lip, tongue, mouth and pharynx

Table 18: Oesophagus - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	608	7.3	6.7	0.85
Female	518	5.7	5.3	0.68
Total	1,126	6.4	6.0	0.76

Age Standardized Incidence Rate per 100,000 world population
Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C15.0 Cervical oesophagus	2	2	4
C15.2 Abdominal oesophagus	1	0	1
C15.3 Upper third of oesophagus	21	17	38
C15.4 Middle third of oesophagus	187	202	389
C15.5 Lower third of oesophagus	178	119	297
C15.8 Overlapping lesion of oesophagus	9	4	13
C15.9 Oesophagus, NOS	210	174	384
Total	608	518	1,126

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	35	37	72
8010 Carcinoma, NOS	20	29	49
8041 Small cell carcinoma, NOS	1	2	3
8070 Squamous cell carcinoma, NOS	446	424	870
8071 Squamous cell carcinoma, keratinizing, NOS	1	0	1
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	1	2
8083 Basaloid squamous cell carcinoma	0	1	1
8140 Adenocarcinoma, NOS	89	22	111
8246 Neuroendocrine carcinoma, NOS	1	0	1
8260 Papillary adenocarcinoma, NOS	2	0	2
8480 Mucinous adenocarcinoma	1	0	1
8490 Signet ring cell carcinoma	9	1	10
8550 Acinar cell carcinoma	1	0	1
8560 Adenosquamous carcinoma	1	1	2
Total	608	518	1,126



**Figure 22: Age specific rates- Oesophagus****Figure 23: ASR, 2006-2011, Oesophagus**

Table 19: Stomach - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	285	3.4	3.1	0.38
Female	112	1.2	1.1	0.14
Total	397	2.3	2.1	0.26

Age Standardized Incidence Rate per 100,000 world population
 Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C16.0 Cardia, NOS	95	44	139
C16.1 Fundus of stomach	6	1	7
C16.2 Body of stomach	4	0	4
C16.3 Gastric antrum	3	1	4
C16.4 Pylorus	11	3	14
C16.5 Lesser curvature of stomach, NOS	2	1	3
C16.6 Greater curvature of stomach, NOS	1	0	1
C16.8 Overlapping lesion of stomach	5	1	6
C16.9 Stomach, NOS	158	61	219
Total	285	112	397

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	21	8	29
8004 Malignant tumour, spindle cell type	1	0	1
8010 Carcinoma, NOS	14	2	16
8070 Squamous cell carcinoma, NOS	17	22	39
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	1	1
8083 Basaloid squamous cell carcinoma	0	1	1
8140 Adenocarcinoma, NOS	177	54	231
8142 Linitis plastica	1	0	1
8144 Adenocarcinoma, intestinal type	24	5	29
8145 Carcinoma, diffuse type	2	1	3
8211 Tubular adenocarcinoma	1	1	2
8480 Mucinous adenocarcinoma	1	1	2
8481 Mucin-producing adenocarcinoma	0	1	1
8490 Signet ring cell carcinoma	20	8	28
8560 Adenosquamous carcinoma	1	0	1
8936 Gastrointestinal stromal sarcoma	5	7	12
Total	285	112	397




Figure 24: Age specific rates - Stomach



Figure 25: ASR, 2006-2011, Stomach

Table 20: Colon and rectum-Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	523	6.2	5.7	0.68
Female	591	6.5	5.8	0.70
Total	1,114	6.4	5.7	0.69

Age Standardized Incidence Rate per 100,000 world population
 Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C18.0 Cecum	27	37	64
C18.1 Appendix	3	7	10
C18.2 Ascending colon	9	10	19
C18.3 Hepatic flexure of colon	6	3	9
C18.4 Transverse colon	16	11	27
C18.5 Splenic flexure of colon	8	3	11
C18.6 Descending colon	10	5	15
C18.7 Sigmoid colon	70	105	175
C18.8 Overlapping lesion of colon	8	10	18
C18.9 Colon, NOS	71	92	163
C19.9 Rectosigmoid junction	41	46	87
C20.9 Rectum, NOS	254	262	516
Total	523	591	1,114

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	37	29	66
8010 Carcinoma, NOS	6	8	14
8032 Spindle cell carcinoma, NOS	1	0	1
8070 Squamous cell carcinoma, NOS	9	6	15
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	2	2
8140 Adenocarcinoma, NOS	418	502	920
8210 Adenocarcinoma in adenomatous polyp	0	1	1
8211 Tubular adenocarcinoma	0	1	1
8240 Carcinoid tumour, NOS	1	4	5
8246 Neuroendocrine carcinoma, NOS	1	0	1
8260 Papillary adenocarcinoma, NOS	1	0	1
8261 Adenocarcinoma in villous adenoma	1	0	1
8263 Adenocarcinoma in tubulovillous adenoma	1	0	1
8310 Clear cell adenocarcinoma, NOS	0	1	1
8480 Mucinous adenocarcinoma	33	28	61
8481 Mucin – producing adenocarcinoma	1	1	2
8490 Signet ring cell carcinoma	8	8	16
8560 Adenosquamous carcinoma	1	0	1
8936 Gastrointestinal stromal sarcoma	4	0	4
Total	523	591	1,114




Figure 26: Age specific rates - Colon and rectum




Figure 27: ASR, 2006-2011 - Colon and rectum

Table 21: Larynx - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	454	5.4	4.9	0.64
Female	47	0.5	0.5	0.05
Total	501	2.9	2.6	0.33

Age Standardized Incidence Rate per 100,000 world population
 Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C32.0 Glottis	241	19	260
C32.1 Supraglottic	120	16	136
C32.2 Subglottis	6	0	6
C32.3 Laryngeal cartilage	12	3	15
C32.8 Overlapping lesion of larynx	8	1	9
C32.9 Larynx, NOS	67	8	75
Total	454	47	501

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	15	0	15
8010 Carcinoma, NOS	3	0	3
8043 Small cell carcinoma, fusiform cell	1	0	1
8051 Verrucous carcinoma, NOS	1	0	1
8070 Squamous cell carcinoma, NOS	425	44	469
8071 Squamous cell carcinoma, keratinizing, NOS	2	1	3
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	2	0	2
8074 Squamous cell carcinoma, spindle cell	1	0	1
8083 Basaloid squamous cell carcinoma	0	2	2
8123 Basaloid carcinoma	1	0	1
8140 Adenocarcinoma, NOS	3	0	3
Total	454	47	501




Figure 28: Age specific rates - Larynx




Figure 29: ASR, 2006-2011 - Larynx

Table 22: Trachea, bronchus and lung - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	788	9.4	8.8	1.15
Female	190	2.1	1.8	0.21
Total	978	5.6	5.2	0.66

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C33.9 Trachea	4	1	5
C34.0 Main bronchus	16	3	19
C34.1 Upper lobe, lung	61	6	67
C34.2 Middle lobe, lung	7	2	9
C34.3 Lower lobe, lung	20	9	29
C34.8 Overlapping lesion of lung	1	0	1
C34.9 Lung, NOS	679	169	848
Total	788	190	978

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	151	38	189
8001 Tumour cells, malignant	1	0	1
8004 Malignant tumour, spindle cell type	2	0	2
8010 Carcinoma, NOS	37	5	42
8012 Large cell carcinoma, NOS	12	2	14
8013 Large cell neuroendocrine carcinoma	2	0	2
8022 Pleomorphic carcinoma	2	0	2
8033 Pseudosarcomatous carcinoma	2	0	2
8041 Small cell carcinoma, NOS	47	6	53
8046 Non-small cell carcinoma	133	24	157
8050 Papillary carcinoma, NOS	1	2	3
8070 Squamous cell carcinoma, NOS	218	24	242
8071 Squamous cell carcinoma, keratinizing, NOS	12	3	15
8140 Adenocarcinoma, NOS	127	58	185
8200 Adenoid cystic carcinoma	2	1	3
8240 Carcinoid tumour, NOS	0	2	2
8243 Goblet cell carcinoid	1	0	1
8246 Neuroendocrine carcinoma, NOS	2	1	3
8250 Bronchiolo alveolar adenocarcinoma, NOS	18	7	25
8251 Alveolar adenocarcinoma	1	1	2
8253 Bronchiolo alveolar carcinoma, mucinous	3	7	10
8260 Papillary adenocarcinoma, NOS	5	2	7
8263 Adenocarcinoma in tubulovillous adenoma	1	0	1
8310 Clear cell adenocarcinoma, NOS	1	0	1
8323 Mixed cell adenocarcinoma	2	0	2
8430 Mucoepidermoid carcinoma	1	0	1
8480 Mucinous adenocarcinoma	2	3	5
8481 Mucin producing adenocarcinoma	1	0	1
8560 Adenosquamous carcinoma	0	1	1
8802 Giant cell sarcoma (except of bone)	1	0	1
8810 Fibrosarcoma, NOS	0	1	1

ICD O code and histology		Male	Female	Total
8973	Pleuropulmonary blastoma	0	1	1
9120	Hemangiosarcoma	0	1	1
Total		788	190	978




Figure 30: Age specific rates - Trachea, bronchus and lung




Figure 31: ASR, 2006-2011 - Trachea, bronchus and lung

Table 23: Skin - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	177	2.1	1.9	0.24
Female	119	1.4	1.1	0.12
Total	296	1.6	1.5	0.18

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and sites	Male	Female	Total
C43.0 Malignant melanoma of skin	1	0	1
C43.4 Malignant melanoma of scalp and neck	0	1	1
C43.5 Malignant melanoma of trunk	3	7	10
C43.6 Malignant melanoma of upper limb, including shoulder	0	4	4
C43.7 Malignant melanoma of lower limb, including hip	17	13	30
C43.9 Malignant melanoma of skin, unspecified	7	7	14
C44.0 Skin of lip, NOS	1	2	3
C44.1 Eyelid	4	10	14
C44.2 External ear	4	4	8
C44.3 Skin, other & unspec parts of face	17	11	28
C44.4 Skin of scalp and neck	19	8	27
C44.5 Skin of trunk	15	14	29
C44.6 Skin of upper limb and shoulder	4	5	9
C44.7 Skin of lower limb and hip	61	18	79
C44.9 Skin, NOS	24	15	39
Total	177	119	296

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	1	0	1
8004 Malignant tumor, spindle cell type	1	0	1
8010 Carcinoma, NOS	2	2	4
8032 Spindle cell carcinoma, NOS	1	3	4
8051 Verrucous carcinoma, NOS	2	1	3
8052 Papillary squamous cell carcinoma	1	0	1
8070 Squamous cell carcinoma, NOS	107	36	143
8071 Squamous cell carcinoma, keratinizing, NOS	2	2	4
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	2	2
8090 Basal cell carcinoma, NOS	20	25	45
8092 Infiltrating basal cell carcinoma, NOS	1	1	2
8094 Basosquamous carcinoma	0	1	1
8097 Basal cell carcinoma, nodular	2	1	3
8102 Trichilemmocarcinoma	1	0	1
8140 Adenocarcinoma, NOS	1	3	4
8410 Sebaceous adenocarcinoma	2	5	7
8430 Mucoepidermoid carcinoma	1	0	1
8720 Malignant melanoma, NOS (except juvenile melanoma)	25	26	51
8721 Nodular melanoma	1	3	4
8723 Malignant melanoma, regressing	0	1	1

ICD O code and histology		Male	Female	Total
8744	Acral lentiginous melanoma, malignant	1	2	3
8772	Spindle cell melanoma, NOS	1	0	1
8832	Dermatofibrosarcoma, NOS	4	5	9
Total		177	119	296




Figure 32: Age specific rates - Skin




Figure 33: ASR, 2006-2011, Skin

Table 24: Breast - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	50	0.6	0.5	0.07
Female	2,419	26.5	23.3	2.65
Total	2,469	14.1	12.2	1.40

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C50.2 Upper-inner quadrant of breast	0	5	5
C50.3 Lower-inner quadrant of breast	0	2	2
C50.4 Upper-outer quadrant of breast	0	25	25
C50.5 Lower-outer quadrant of breast	0	4	4
C50.6 Axillary tail of breast	0	2	2
C50.8 Overlapping lesion of breast	0	1	1
C50.9 Breast, NOS	50	2,380	2,430
Total	50	2,419	2,469

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	5	193	198
8004 Malignant tumour, spindle cell type	0	1	1
8010 Carcinoma, NOS	2	40	42
8032 Spindle cell carcinoma, NOS	0	1	1
8050 Papillary carcinoma, NOS	2	11	13
8070 Squamous cell carcinoma, NOS	1	4	5
8140 Adenocarcinoma, NOS	2	19	21
8200 Adenoid cystic carcinoma	0	1	1
8211 Tubular adenocarcinoma	0	4	4
8246 Neuroendocrine carcinoma, NOS	0	2	2
8260 Papillary adenocarcinoma, NOS	0	5	5
8310 Clear cell adenocarcinoma, NOS	0	1	1
8480 Mucinous adenocarcinoma	1	41	42
8500 Infiltrating duct carcinoma, NOS	33	1,940	1,973
8501 Comedocarcinoma, NOS	0	1	1
8502 Secretory carcinoma of breast	1	0	1
8504 Intracystic carcinoma, NOS	0	2	2
8510 Medullary carcinoma, NOS	0	19	19
8520 Lobular carcinoma, NOS	3	92	95
8522 Infiltrating duct and lobular carcinoma	0	10	10
8523 Infiltrating duct mixed with other types of carcinoma	0	9	9
8524 Infiltrating lobular mixed with other types of carcinoma	0	4	4
8530 Inflammatory carcinoma	0	1	1
8560 Adenosquamous carcinoma	0	1	1
8575 Metaplastic carcinoma, NOS	0	5	5
8801 Spindle cell sarcoma	0	1	1
8980 Carcinosarcoma, NOS	0	1	1
9020 Phyllodes tumour, malignant	0	8	8

ICD O code and histology		Male	Female	Total
9120	Hemangiosarcoma	0	2	2
Total		50	2,419	2,469




Figure 34: Age specific rates - Breast




Figure 35: ASR, 2006-2011 - Breast

Table 25: Cervix Uteri - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Female	839	9.2	8.2	0.98

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Female
C53.0 Endocervix	12
C53.1 Exocervix	4
C53.8 Overlapping lesion of cervix uteri	1
C53.9 Cervix uteri	822
Total	839

ICD O code and histology	Female
8000 Neoplasm, malignant	76
8010 Carcinoma, NOS	27
8050 Papillary carcinoma, NOS	2
8052 Papillary squamous cell carcinoma	1
8070 Squamous cell carcinoma, NOS	394
8071 Squamous cell carcinoma, keratinizing, NOS	102
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	168
8073 Squamous cell carcinoma, small cell, nonkeratinizing	1
8076 Squamous cell carcinoma, microinvasive	1
8083 Basaloid squamous cell carcinoma	2
8140 Adenocarcinoma, NOS	47
8246 Neuroendocrine carcinoma, NOS	1
8260 Papillary adenocarcinoma, NOS	2
8310 Clear cell adenocarcinoma, NOS	3
8480 Mucinous adenocarcinoma	4
8481 Mucin producing adenocarcinoma	1
8560 Adenosquamous carcinoma	4
8850 Liposarcoma, NOS	1
8935 Stromal sarcoma, NOS	1
8980 Carcinosarcoma, NOS	1
Total	839



**Figure 36: Age specific rates - Cervix uteri****Figure 37: ASR, 2006-2011 - Cervix uteri**

Table 26: Uterus - Incidence data 2011

Group	Number	%	ASR	Cum. rate
Female	411	4.5	4.1	0.53

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Female
C54.1 Endometrium	366
C54.8 Overlapping lesion of corpus uteri	1
C55.9 Uterus, NOS	44
Total	411

ICD O code and histology	Female
8000 Neoplasm, malignant	14
8010 Carcinoma, NOS	6
8032 Spindle cell carcinoma, NOS	1
8050 Papillary carcinoma, NOS	1
8070 Squamous cell carcinoma, NOS	5
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	4
8140 Adenocarcinoma, NOS	106
8260 Papillary adenocarcinoma, NOS	9
8263 Adenocarcinoma in tubulovillous adenoma	2
8310 Clear cell adenocarcinoma, NOS	3
8380 Endometrioid adenocarcinoma, NOS	210
8441 Serous cystadenocarcinoma, NOS	1
8460 Papillary serous cystadenocarcinoma	1
8560 Adenosquamous carcinoma	3
8800 Sarcoma, NOS	1
8801 Spindle cell sarcoma	1
8890 Leiomyosarcoma, NOS	17
8930 Endometrial stromal sarcoma, NOS	9
8931 Endometrial stromal sarcoma, low grade	2
8933 Adenosarcoma	1
8935 Stromal sarcoma, NOS	2
8950 Mullerian mixed tumour	4
8980 Carcinosarcoma, NOS	7
9100 Choriocarcinoma, NOS	1
Total	411




Figure 38: Age specific rates - Uterus




Figure 39: ASR, 2006-2011 - Uterus

Table 27: Ovary - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Female	681	7.5	6.7	0.78

Age Standardized Incidence Rate per 100,000 world population
Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Female
C56.9 Ovary	681
Total	681

ICD O code and histology	Female
8000 Neoplasm, malignant	78
8010 Carcinoma, NOS	29
8032 Spindle cell carcinoma, NOS	1
8050 Papillary carcinoma, NOS	4
8052 Papillary squamous cell carcinoma	1
8070 Squamous cell carcinoma, NOS	2
8071 Squamous cell carcinoma, keratinizing, NOS	1
8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1
8120 Transitional cell carcinoma, NOS	1
8140 Adenocarcinoma, NOS	67
8260 Papillary adenocarcinoma, NOS	9
8263 Adenocarcinoma in tubulovillous adenoma	1
8310 Clear cell adenocarcinoma, NOS	14
8320 Granular cell carcinoma	1
8380 Endometrioid adenocarcinoma, NOS	44
8440 Cystadenocarcinoma, NOS	3
8441 Serous cystadenocarcinoma, NOS	95
8450 Papillary cystadenocarcinoma, NOS	2
8460 Papillary serous cystadenocarcinoma	190
8461 Serous surface papillary carcinoma	13
8470 Mucinous cystadenocarcinoma, NOS	24
8471 Papillary mucinous cystadenocarcinoma	1
8480 Mucinous adenocarcinoma	30
8481 Mucin producing adenocarcinoma	1
8620 Granulosa cell tumour, malignant	19
8631 Sertoli- Leydig cell tumour, poorly differentiated	1
8890 Leiomyosarcoma, NOS	3
9000 Brenner tumour, malignant	2
9060 Dysgerminoma	13
9070 Embryonal carcinoma, NOS	2
9071 Yolk sac tumour	14
9080 Teratoma, malignant, NOS	5
9085 Mixed germ cell tumour	8
9100 Choriocarcinoma, NOS	1
Total	681




Figure 40: Age specific rates - Ovary




Figure 41: ASR, 2006-2011 - Ovary

Table 28: Prostate gland - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	480	5.7	5.5	0.70

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site		Male
C61.9	Prostate gland	480
Total		480

ICD O code and histology		Male
8000	Neoplasm, malignant	85
8010	Carcinoma, NOS	18
8120	Transitional cell carcinoma, NOS	1
8140	Adenocarcinoma, NOS	247
8310	Clear cell adenocarcinoma, NOS	1
8490	Signet ring cell carcinoma	1
8500	Infiltrating duct carcinoma, NOS	4
8550	Acinar cell carcinoma	123
Total		480




Figure 42: Age specific rates - Prostate gland




Figure 43: ASR, 2006-2011 - Prostate gland

Table 29: Urinary bladder - incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	243	2.9	2.8	0.34
Female	64	0.7	0.6	0.08
Total	307	1.8	1.6	0.20

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C67.9 Urinary bladder, NOS	243	64	307
Total	243	64	307

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	10	4	14
8010 Carcinoma, NOS	4	0	4
8050 Papillary carcinoma, NOS	1	1	2
8070 Squamous cell carcinoma, NOS	13	6	19
8120 Transitional cell carcinoma, NOS	152	41	193
8130 Papillary transitional cell carcinoma	53	10	63
8140 Adenocarcinoma, NOS	8	1	9
8230 Solid carcinoma, NOS	1	0	1
8260 Papillary adenocarcinoma, NOS	0	1	1
8550 Acinar cell carcinoma	1	0	1
Total	243	64	307




Figure 44: Age specific rates - Urinary bladder



Figure 45: ASR, 2006-2011 - Urinary bladder

Table 30: Thyroid gland - incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	167	2.0	1.6	0.16
Female	760	8.3	6.8	0.67
Total	927	5.3	4.3	0.42

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C73.9 Thyroid gland	167	760	927
Total	167	760	927

ICD O code and histology	Male	Female	Total
8000 Neoplasm, malignant	6	9	15
8010 Carcinoma, NOS	0	6	6
8020 Carcinoma, undifferentiated, NOS	0	1	1
8021 Carcinoma, anaplastic, NOS	7	25	32
8070 Squamous cell carcinoma, NOS	3	1	4
8140 Adenocarcinoma, NOS	1	0	1
8260 Papillary adenocarcinoma, NOS	80	339	419
8290 Oxyphilic adenocarcinoma	1	6	7
8310 Clear cell adenocarcinoma, NOS	1	0	1
8330 Follicular adenocarcinoma, NOS	24	152	176
8335 Follicular carcinoma, minimally invasive	0	5	5
8340 Papillary carcinoma, follicular variant	29	135	164
8341 Papillary microcarcinoma	7	68	75
8343 Papillary carcinoma, encapsulated	0	1	1
8350 Nonencapsulated sclerosing carcinoma	0	1	1
8430 Mucoepidermoid carcinoma	0	1	1
8510 Medullary carcinoma, NOS	8	10	18
Total	167	760	927




Figure 46: Age specific rates - Thyroid gland



Figure 47: ASR, 2006-2011 - Thyroid gland

Table 31: Lymphoma - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	442	5.3	4.5	0.51
Female	304	3.3	2.9	0.31
Total	746	4.3	3.7	0.41

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C81.0 Nodular lymphocyte predominant Hodgkin lymphoma	10	2	12
C81.1 Nodular sclerosis (classical) Hodgkin lymphoma	20	17	37
C81.2 Mixed cellularity (classical) Hodgkin lymphoma	13	5	18
C81.9 Hodgkin lymphoma, unspecified	33	21	54
C82.0 Follicular lymphoma grade I	1	0	1
C82.2 Follicular lymphoma grade III, unspecified	1	1	2
C82.7 Other type of follicular lymphoma	4	6	10
C82.9 Follicular lymphoma, unspecified	37	22	59
C83.0 Small cell B cell lymphoma	6	3	9
C83.3 Diffuse large B-cell lymphoma	77	62	139
C83.4 Immunoblastic diffuse lymphoma	1	1	2
C83.5 Lymphoblastic (diffuse) lymphoma	14	3	17
C83.7 Burkitt lymphoma	3	0	3
C83.8 Other non-follicular lymphoma	7	3	10
C84.0 Mycosis fungoides	3	2	5
C84.4 Peripheral T-cell lymphoma	13	6	19
C84.5 Other mature T/NK-cell lymphomas	12	8	20
C85.9 Non-Hodgkin lymphoma, unspecified	182	139	321
C96.0 Multifocal and multisystemic Langerhans-cell histiocytosis	5	3	8
Total	442	304	746


**Figure 48: Age specific rates - Lymphoma**

Table 32: Leukaemia - Incidence data 2011

Group	Number	%	ASR	Cum Rate
Male	374	4.5	3.9	0.36
Female	323	3.5	3.3	0.31
Total	697	4.0	3.6	0.33

Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

ICD 10 code and site	Male	Female	Total
C91.0 Acute lymphoblastic leukaemia (ALL)	140	91	231
C91.1 Chronic lymphocytic leukaemia of B cell type	31	13	44
C91.3 Prolymphocytic leukaemia of B cell type	1	0	1
C91.4 Hairy cell leukaemia	4	2	6
C92.0 Acute myeloblastic leukaemia	77	82	159
C92.1 Chronic myeloid leukaemia	69	68	137
C92.3 Myeloid sarcoma	0	1	1
C92.4 Acute promyelocytic leukaemia	11	19	30
C92.5 Acute myelomonocytic leukaemia	13	16	29
C92.9 Myeloid leukaemia, unspecified	1	1	2
C93.0 Acute monoblastic/monocytic leukaemia	7	7	14
C94.2 Acute megakaryoblastic leukaemia	3	6	9
C94.4 Acute panmyelosis with myelofibrosis	7	5	12
C95.0 Acute leukaemia of unspecified cell type	8	11	19
C95.9 Leukemia, unspecified	2	1	3
Total	374	323	697


**Figure 49: Age specific rates - Leukaemia**

Table 33: Cancer Incidence by site and histological type, 2011

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
Lip, tongue and mouth (C00-C06)							
800	Neoplasms, NOS	70	4.6	18	4.3	88	4.5
801-804	Epithelial neoplasms, NOS	19	1.2	12	2.9	31	1.6
805-808	Squamous cell neoplasms	1,414	92.8	362	86.8	1,776	91.5
814-838	Adenocarcinomas	8	0.5	10	2.4	18	0.9
843	Mucoepidermoid neoplasm	6	0.4	10	2.4	16	0.8
844-849	Cystic, mucinous and serous neoplasms	0	0.0	1	0.2	1	0.1
856- 857	Complex epithelial neoplasms	0	0.0	1	0.2	1	0.1
872-879	Melanomas	3	0.2	2	0.5	5	0.3
880	Soft tissue tumours and sarcomas	1	0.1	0	0.0	1	0.1
881-883	Fibromatous neoplasms	1	0.1	0	0.0	1	0.1
889-892	Myomatous neoplasms	2	0.1	0	0.0	2	0.1
912-916	Blood vessel tumours	0	0.0	1	0.2	1	0.1
	Total	1,524	100.0	417	100.0	1,941	100.0
Parotid and other salivary gland (C07-C08)		No	%	No	%	No	%
800	Neoplasms, NOS	4	10.8	2	4.3	6	7.1
801-804	Epithelial neoplasms, NOS	3	8.1	4	8.5	7	8.3
805-808	Squamous cell neoplasms	6	16.2	5	10.6	11	13.1
814-838	Adenocarcinomas	8	21.6	11	23.4	19	22.6
843	Mucoepidermoid neoplasms	12	32.4	20	42.6	32	38.1
850-854	Ductal & lobular neoplasms	3	8.1	0	0.0	3	3.6
855	Acinar cell neoplasms	0	0.0	4	8.5	4	4.8
880	Soft tissue tumours and sarcomas	0	0.0	1	2.1	1	1.2
893-899	Complex mixed and stromal neoplasms	1	2.7	0	0.0	1	1.2
	Total	37	100.0	47	100.0	84	100.0
Tonsil and Pharynx (C09-C14)		No	%	No	%	No	%
800	Neoplasms, NOS	36	6.7	8	10.5	44	10.5
801-804	Epithelial neoplasms, NOS	11	2.0	2	2.6	13	2.6
805-808	Squamous cell neoplasms	491	90.8	65	85.5	556	85.5
814-838	Adenocarcinomas	2	0.4	0	0.0	2	0.0
843	Mucoepidermoid neoplasms	1	0.2	0	0.0	1	0.0
889-892	Myomatous neoplasms	0	0.0	1	1.3	1	1.3
	Total	541	100.0	76	100.0	617	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
Digestive organs (C15-C25)							
800	Neoplasms, NOS	123	7.2	105	7.3	228	7.2
801-804	Epithelial neoplasms, NOS	55	3.2	50	3.5	105	3.3
805-808	Squamous cell neoplasms	499	29.0	475	33.0	974	30.9
812-813	Transitional cell neoplasms	1	0.1	0	0.0	1	0.0
814-838	Adenocarcinomas	932	54.2	721	50.1	1,653	52.4
844-849	Cystic, mucinous and serous neoplasms	79	4.6	57	4.0	136	4.3
850-854	Ductal and lobular neoplasms	2	0.1	4	0.3	6	0.2
855	Acinar cell neoplasms	1	0.1	1	0.1	2	0.1
856-857	Complex epithelial neoplasms	4	0.2	2	0.1	6	0.2
872-879	Melanomas	1	0.1	0	0.0	1	0.0
893-899	Complex mixed and stromal neoplasms	21	1.2	22	1.5	43	1.4
904	Synovial neoplasms	0	0.0	1	0.1	1	0.0
	Total	1,718	100.0	1,438	100.0	3,156	100.0

Respiratory and intrathoracic organs (C30 -C38)		No	%	No	%	No	%
800	Neoplasms, NOS	176	13.4	41	14.7	217	13.6
801-804	Epithelial neoplasms, NOS	243	18.5	38	13.7	281	17.6
805-808	Squamous cell neoplasms	690	52.5	84	30.2	774	48.6
812-813	Transitional cell neoplasms	3	0.2	1	0.4	4	0.3
814-838	Adenocarcinomas	175	13.3	92	33.1	267	16.8
843	Mucoepidermoid neoplasms	1	0.1	0	0.0	1	0.1
844-849	Cystic, mucinous and serous neoplasms	3	0.2	3	1.1	6	0.4
855	Acinar cell neoplasms	0	0.0	1	0.4	1	0.1
856-857	Complex epithelial neoplasms	0	0.0	1	0.4	1	0.1
858	Thymic epithelial neoplasms	8	0.6	7	2.5	15	0.9
872-879	Melanomas	1	0.1	0	0.0	1	0.1
880	Soft tissue tumours and sarcomas	1	0.1	1	0.4	2	0.1
881-883	Fibromatous neoplasms	0	0.0	1	0.4	1	0.1
889-892	Myomatous neoplasms	3	0.2	1	0.4	4	0.3
893-899	Complex mixed and stromal neoplasms	0	0.0	1	0.4	1	0.1
906-909	Germ cell neoplasms	7	0.5	3	1.1	10	0.6
912-916	Blood vessel tumours	0	0.0	2	0.7	2	0.1
935-937	Miscellaneous tumours	0	0.0	1	0.4	1	0.1
949-952	Neuroepitheliomatous neoplasms	2	0.2	0	0.0	2	0.1
954-957	Nerve sheath tumours	2	0.2	0	0.0	2	0.1
	Total	1,315	100.0	278	100.0	1,593	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
Bones, joints and articular cartilage (C40-C41)							
800	Neoplasms, NOS	1	1.7	0	0.0	1	0.9
912-916	Blood vessel tumours	0	0.0	1	2.1	1	0.9
918-924	Osseous and chondromatous neoplasms	44	73.3	27	57.4	71	66.4
925	Giant cell tumours	2	3.3	0	0.0	2	1.9
926	Miscellaneous bone tumours	10	16.7	18	38.3	28	26.2
927-934	Odontogenic tumours	2	3.3	1	2.1	3	2.8
935-937	Miscellaneous tumour	1	1.7	0	0.0	1	0.9
	Total	60	100	47	100.0	107	100.0

Skin (C43-C44)		No	%	No	%	No	%
800	Neoplasms, NOS	2	1.1	0	0.0	2	0.7
801-804	Epithelial neoplasms, NOS	3	1.7	5	4.2	8	2.7
805-808	Squamous cell neoplasms	112	63.3	41	34.5	153	51.7
809-811	Basal cell neoplasms	24	13.6	28	23.5	52	17.6
814-838	Adenocarcinomas	1	0.6	3	2.5	4	1.4
839-842	Adnexal and skin appendage neoplasms	2	1.1	5	4.2	7	2.4
843	Mucoepidermoid neoplasms	1	0.6	0	0.0	1	0.3
872-879	Melanomas	28	15.8	32	26.9	60	20.3
881-883	Fibromatous neoplasms	4	2.3	5	4.2	9	3.0
	Total	177	100.0	119	100.0	296	100.0

Mesothelioma (C45)		No	%	No	%	No	%
905	Mesothelial neoplasms	6	100.0	2	100.0	8	100.0
	Total	6	100.0	2	100.0	8	100.0

Connective and soft tissue (C47 & C49)		No	%	No	%	No	%
800	Neoplasms, NOS	11	12.1	3	3.7	14	8.1
880	Soft tissue tumours and sarcomas	18	19.8	23	28.4	41	23.8
881-883	Fibromatous neoplasms	10	11.0	8	9.9	18	10.5
884	Myxomatous neoplasms	1	1.1	0	0.0	1	0.6
885-888	Lipomatous neoplasms	12	13.2	5	6.2	17	9.9
889-892	Myomatous neoplasms	16	17.6	14	17.3	30	17.4
904	Synovial neoplasms	10	11.0	14	17.3	24	14.0
912-916	Blood vessel tumours	0	0.0	4	4.9	4	2.3
954-957	Nerve sheath tumours	13	14.3	9	11.1	22	12.8
958	Granular cell tumours and alveolar soft part sarcomas	0	0.0	1	1.2	1	0.6
	Total	91	100.0	81	100.0	172	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
Breast (C50)							
800	Neoplasms, NOS	5	10.0	194	8.0	199	8.1
801-804	Epithelial neoplasms, NOS	2	4.0	41	1.7	43	1.7
805-808	Squamous cell neoplasms	3	6.0	15	0.6	18	0.7
814-838	Adenocarcinomas	2	4.0	32	1.3	34	1.4
844-849	Cystic, mucinous and serous neoplasms	1	2.0	41	1.7	42	1.7
850-854	Ductal and lobular neoplasms	37	74.0	2,078	85.9	2,115	85.7
856-857	Complex epithelial neoplasms	0	0.0	6	0.2	6	0.2
880	Soft tissue tumours and sarcomas	0	0.0	1	0.0	1	0.0
893-899	Complex mixed and stromal neoplasms	0	0.0	1	0.0	1	0.0
900-903	Fibroepithelial neoplasms	0	0.0	8	0.3	8	0.3
912-916	Blood vessel tumours	0	0.0	2	0.1	2	0.1
	Total	50	100.0	2,419	100.0	2,469	100.0

Female genital organs (C51-C58)		No	%	No	%	No	%
800	Neoplasms, NOS			171	8.55	171	8.55
801-804	Epithelial neoplasms, NOS			67	3.35	67	3.35
805-808	Squamous cell neoplasms			728	36.4	728	36.4
809-811	Basal cell neoplasms			1	0.05	1	0.05
812-813	Transitional cell neoplasms			1	0.05	1	0.05
814-838	Adenocarcinomas			525	26.25	525	26.25
844-849	Cystic, mucinous and serous neoplasms			366	18.3	366	18.3
850-854	Ductal and lobular neoplasms			1	0.05	1	0.05
856-857	Complex epithelial neoplasms			7	0.35	7	0.35
859-867	Specialized gonadal neoplasms			20	0.1	20	0.1
872-879	Melanomas			1	0.05	1	0.05
880	Soft tissue tumours and sarcoma			3	0.15	3	0.15
885-888	Lipomatous neoplasms			1	0.05	1	0.05
889-892	Myomatous neoplasms			22	1.1	22	1.1
893-899	Complex mixed and stromal neoplasms			27	1.35	27	1.35
900-903	Fibroepithelial neoplasms			2	0.1	2	0.1
906-909	Germ cell neoplasms			42	2.1	42	2.1
910	Trophoblastic neoplasms			15	0.75	15	0.75
	Total			2,000	100	2,000	100

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
Male genital organs (C60-C63)							
800	Neoplasms, NOS	88	14.3			88	14.3
801-804	Epithelial neoplasms, NOS	18	2.9			18	2.9
805-808	Squamous cell neoplasms	71	11.6			71	11.6
812-813	Transitional cell neoplasms	1	0.2			1	0.2
814-838	Adenocarcinomas	248	40.4			248	40.4
844-849	Cystic, mucinous and serous neoplasms	1	0.2			1	0.2
850-854	Ductal and lobular neoplasms	4	0.7			4	0.7
855	Acinar cell neoplasms	123	20.0			123	20.0
889-892	Mayomatous neoplasms	1	0.2			1	0.2
906-909	Germ cell neoplasms	59	9.6			59	9.6
	Total	614	100.0			614	100.0

Malignant neoplasms of urinary tract (C64-C68)		No	%	No	%	No	%
800	Neoplasms, NOS	12	3.4	6	4.8	18	3.8
801-804	Epithelial neoplasms, NOS	4	1.1	0	0	4	0.8
805-808	Squamous cell neoplasms	15	4.3	8	6.4	23	4.8
812-813	Transitional cell neoplasms	212	60.4	56	44.8	268	56.3
814-838	Adenocarcinomas	98	27.9	40	32	138	29.0
855	Acinar cell neoplasms	1	0.3	0	0	1	0.2
880	Soft tissue tumours and sarcomas	0	0.0	2	1.6	2	0.4
893-899	Complex mixed and stromal neoplasms	8	2.3	12	9.6	20	4.2
954-957	Nerve sheath tumours	1	0.3	1	0.8	2	0.4
	Total	351	100.0	125	100	476	100.0

Eye and Adnexa (C69)		No	%	No	%	No	%
800	Neoplasms, NOS	1	4.3	0	0.0	1	2.5
801-804	Epithelial neoplasms, NOS	1	4.3	0	0.0	1	2.5
805-808	Squamous cell neoplasms	5	21.7	2	11.8	7	17.5
814-838	Adenocarcinomas	0	0.0	1	5.9	1	2.5
872-879	Melanomas	0	0.0	1	5.9	1	2.5
889-892	Mayomatous neoplasms	2	8.7	0	0.0	2	5
949-952	Neuroepitheliomatous neoplasms	14	60.9	13	76.5	27	67.5
	Total	23	100.0	17	100.0	40	100

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
Brain and other parts of central nervous system (C70-C72)							
800	Neoplasms, NOS	3	1.7	5	3.6	8	2.5
935-937	Miscellaneous tumours	1	0.6	0	0.0	1	0.3
938-948	Gliomas	169	93.4	123	89.1	292	91.5
949-952	Neuroepitheliomatous neoplasms	1	0.6	1	0.7	2	0.6
953	Meningiomas	6	3.3	9	6.5	15	4.7
954-957	Nerve sheath tumours	1	0.6	0	0.0	1	0.3
	Total	181	100.0	138	100.0	319	100.0

Thyroid and other endocrine glands (C73-C75)		No	%	No	%	No	%
800	Neoplasms, NOS	6	3.2	9	1.2	15	1.5
801-804	Epithelial neoplasms, NOS	10	5.3	32	4.1	42	4.3
805-808	Squamous cell neoplasms	3	1.6	1	0.1	4	0.4
814-838	Adenocarcinomas	146	76.8	713	91.4	859	88.6
843	Mucoepidermoid neoplasms	0	0.0	2	0.3	2	0.2
850-854	Ductal and lobular neoplasms	8	4.2	10	1.3	18	1.9
906-909	Germ cell neoplasms	1	0.5	1	0.1	2	0.2
935-937	Miscellaneous tumours	0	0.0	1	0.1	1	0.1
949-952	Neuroepitheliomatous neoplasms	13	6.8	9	1.2	22	2.3
868-871	Paragangliomas and glomus tumour	3	1.6	2	0.3	5	0.5
	Total	190	100.0	780	100.0	970	100.0

Other and unspecified sites (C26, C39, C48, C76 & C80)		No	%	No	%	No	%
800	Neoplasms, NOS	142	29.0	115	14.7	257	32.1
801-804	Epithelial neoplasms, NOS	71	14.5	32	4.1	103	12.9
805-808	Squamous cell neoplasms	110	22.5	31	4.0	141	17.6
812-813	Transitional cell neoplasms	1	0.2	0	0.0	1	0.1
814-838	Adenocarcinomas	124	25.4	100	12.8	224	28.0
843	Mucoepidermoid neoplasms	2	0.4	0	0.0	2	0.3
844-849	Cystic, mucinous and serous neoplasms	13	2.7	12	1.5	25	3.1
855	Acinar cell neoplasms	2	0.4	0	0.0	2	0.3
880	Soft tissue tumours and sarcomas	3	0.6	3	0.4	6	0.8
885-888	Lipomatous neoplasms	3	0.6	0	0.0	3	0.4
889-892	Myomatous neoplasms	0	0.0	2	0.3	2	0.3
893-899	Complex mixed and stromal neoplasms	6	1.2	7	0.9	13	1.6
906-909	Germ cell neoplasms	7	1.4	6	0.8	13	1.6
935-937	Miscellaneous tumours	1	0.2	0	0.0	1	0.1
949-952	Neuroepitheliomatous neoplasms	3	0.6	1	0.1	4	0.5
954-957	Nerve sheath tumours	1	0.2	2	0.3	3	0.4
	Total	489	100.0	311	39.9	800	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
Lymphoma (C81-C85 & C96)							
959	Malignant lymphomas NOS	19	4.3	15	4.9	34	4.6
959	Malignant lymphoma, non-Hodgkin, NOS	163	36.9	124	40.8	287	38.5
965-966	Hodgkin lymphoma	76	17.2	45	14.8	121	16.2
967-969	Mature B-cell lymphomas	137	31.0	98	32.2	235	31.5
970-971	Mature T-and NK-Cell lymphomas	28	6.3	16	5.3	44	5.9
972	Precursor cell lymphoblastic lymphoma	14	3.2	3	1.0	17	2.3
975	Neoplasms of histiocytes and accessory lymphoid cells	5	1.1	3	1.0	8	1.1
	Total	442	100.0	304	100.0	746	100.0

Leukaemia (C91-C95)		No	%	No	%	No	%
980	Leukaemias, NOS	10	2.7	12	3.7	22	3.2
982-983	Lymphoid leukaemias	172	46.0	104	32.2	276	39.6
984-993	Myeloid leukaemias	186	49.7	199	61.6	385	55.2
994	Other leukaemias	6	1.6	8	2.5	14	2.0
	Total	374	100	323	100	697	100

Multiple myeloma and malignant plasma cell neoplasms (C90)		No	%	No	%	No	%
973	Plasma cell tumours	161	100	167	100	328	100
	Total	161	100	167	100	328	100

Myeloproliferative and myelodysplastic syndromes (D45-47)		No	%	No	%	No	%
995-996	Chronic myeloproliferative disorders	4	15.4	7	30.4	11	22.4
998	Myelodysplastic syndromes	22	84.6	16	69.6	38	77.6
	Total	26	100.0	23	100.0	49	100.0

Staging information of common cancers - 2011

Figures 50,51 and 52 give the staging information of the three main cancers namely breast, cervical and oral cancers. Information on staging was available for 1,405 (56.8%) of breast cancers, 469 (56%) cervical cancers and 383 (20%) of oral cancers. The percentages computed are out of the cancers with staging information.




Figure 50: Stage at diagnosis – Breast cancer




Figure 51: Stage at diagnosis – Cervical cancer




Figure 52: Stage at diagnosis – Oral cancer

Table 34: Basis of diagnosis of cancer patients - 2011

Basis of diagnosis	Frequency	Percentage
Diagnosed microscopically		
Histology of primary tumour	14,752	84.38
Cytology/Haematology	1,116	6.38
Histology of metastasis	892	5.1
Subtotal	16,760	95.87
Diagnosed non-microscopically		
Clinical only	66	0.38
Clin. Invest. Including Ult Sound, X-ray, CT etc.	556	3.18
Exploratory Surgery	6	0.03
Specific Biochemical/Immunological test	59	0.34
Subtotal	687	3.93
Unknown/Not recoded	35	0.20
Total	17,482	100.00


**Figure 53: Basis of diagnosis - 2011**

Table 35: Cancer treatment - 2011

Treatment	Frequency	Percentage
Surgery (S) only	867	5.0
Radiotherapy (R) only	1,207	6.9
Chemotherapy (C) only	1,791	10.2
Hormone (H) only	48	0.3
Other -Symptomatic treatment (O) only	387	2.2
S + R	906	5.2
S + C	1,227	7.0
S + H	116	0.7
S + O	155	0.9
R + C	1,714	9.8
R + H	35	0.2
R + O	336	1.9
C + H	45	0.3
C + O	737	4.2
H + O	14	0.1
S + R + C	1,073	6.1
S + R + H	146	0.8
S + R + O	320	1.8
S + C + H	136	0.8
S + C + O	333	1.9
S + H + O	26	0.1
R + C + H	41	0.2
R + C + O	632	3.6
R + H + O	22	0.1
C + H + O	21	0.1
S + R + C + H	599	3.4
S + R + C + O	362	2.1
S + C + H + O	51	0.3
S + R + H + O	44	0.3
R + C + H + O	24	0.1
S + R + C + H + O	153	0.9
Treatment unknown	3,914	22.4
Total	17,482	100.0




Figure 54: Percentage of patients who received different types of treatment

Table 36: Childhood cancer incidence data (0-14 years) - 2011

Site Group	ICD - O - 3 Histology		Male	Female	Total
I Leukaemia, myeloproliferative diseases, and myelodysplastic diseases					
a Lymphoid leukaemias	9835	Precursor cell lymphoblastic leukaemia, NOS	39	38	77
	9836	Precursor B-cell lymphoblastic leukaemia	30	28	58
	9837	Precursor T-cell lymphoblastic leukaemia	8	1	9
	9940	Hairy cell leukaemia	1	0	1
b Acute myeloid leukaemias	9861	Acute myeloid leukaemia, NOS	1	2	3
	9866	Acute promyelocytic leukaemia, t (15;17) (q22; q11-12)	1	0	1
	9867	Acute myelomonocytic leukaemia	1	2	3
	9872	Acute myeloid leukaemia minimal differentiation	0	1	1
	9873	Acute myeloid leukaemia without maturation	1	1	2
	9874	Acute myeloid leukaemia with maturation	3	3	6
	9891	Acute monocytic leukaemia	1	3	4
	9910	Acute megakaryoblastic leukaemia	1	2	3
c Chronic myeloproliferative diseases	9863	Chronic myeloid leukaemia, NOS	0	1	1
	9875	Chronic myelogenous leukaemia, BCR/ABL	0	1	1
d Myelodysplastic syndr. and other myeloproliferative disorders	9946	Juvenile myelomonocytic leukaemia	1	2	3
	9987	Therapy-related myelodysplastic syndrome	1	0	1
e Unspecified and other specified leukaemias	9800	Leukaemia, NOS	1	1	2
	9805	Acute biphenotypic leukaemia	0	1	1
Total			90	87	177
II Lymphoma and reticuloendothelial neoplasms					
a Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	0	1	1
	9652	Hodgkin lymphoma, mixed cellularity, NOS	1	2	3
	9659	Hodgkin lymphoma, nodular lymphocyte predominant	2	0	2
	9663	Hodgkin lymphoma, nodular sclerosis, NOS	1	1	2
b Non-Hodgkin lymphomas	9591	Malignant lymphoma, non-Hodgkin, NOS	1	2	3
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	0	2	2
	9702	Mature T-cell lymphoma, NOS	0	1	1
	9714	Anaplastic large cell lymphoma, T cell and Null Cell type	3	1	4
	9727	Precursor cell lymphoblastic lymphoma, NOS	5	0	5
	9728	Precursor B-cell lymphoblastic lymphoma	1	0	1
	9729	Precursor T-cell lymphoblastic lymphoma	1	1	2
c Burkitt lymphoma	9687	Burkitt lymphoma, NOS	2	0	2
d Miscellaneous lymphoreticular neoplasms	9754	Langerhans cell histiocytosis, disseminated	5	3	8
Total			22	14	36
III CNS and miscellaneous intracranial and intraspinal neoplasms					
a Ependymomas and choroid plexus tumour	9390	Choroid plexus carcinoma	0	1	1
	9391	Ependymoma, NOS	3	2	5
	9392	Ependymoma, anaplastic	0	3	3
b Astrocytomas	9380	Glioma, malignant	0	1	1
	9400	Astrocytoma, NOS	2	2	4
	9401	Astrocytoma, anaplastic	2	2	4
	9424	Pleomorphic xanthoastrocytoma	1	0	1
	9444	Glioblastoma	1	0	1

Site Group	ICD - O - 3 Histology	Male	Female	Total	
c	Intracranial and intraspinal embryonal tumours	9470 Medulloblastoma, NOS	5	8	13
		9501 Medulloepithelioma, NOS	0	1	1
d	Other gliomas	9380 Glioma, malignant	5	4	9
f	Unspecified intracranial and intraspinal neoplasms	8000 Neoplasm, malignant	1	1	2
Total			20	25	45
IV Neuroblastoma and other peripheral nervous cell tumours					
a	Neuroblastoma and ganglioneuroblastoma	9490 Ganglioneuroblastoma	1	2	3
		9500 Neuroblastoma, NOS	15	8	23
Total			16	10	26
V Retinoblastoma					
		9510 Retinoblastoma, NOS	14	13	27
Total			14	13	27
VI Renal tumours					
a	Nephroblastoma and other nonepithelial renal tumours	8960 Nephroblastoma, NOS	8	11	19
b	Renal carcinomas	8312 Renal cell carcinoma, NOS	0	1	1
c	Unspecified malignant renal tumours	8000 Neoplasm, malignant	1	0	1
Total			9	12	21
VII Hepatic tumours					
a	Hepatoblastoma	8970 Hepatoblastoma	5	10	15
b	Hepatic carcinoma	8170 Hepatocellular carcinoma, NOS	1	0	1
Total			6	10	16
VIII Malignant bone tumours					
a	Osteosarcomas	9180 Osteosarcoma, NOS	3	3	6
		9181 Chondroblastic osteosarcoma	1	1	2
		9192 Parosteal osteosarcoma	0	1	1
c	Ewing tumour and related sarcoma of bone	9260 Ewing sarcoma	2	5	7
Total			6	10	16
IX Soft tissue and other extraosseous sarcomas					
a	Rhabdomyosarcomas	8900 Rhabdomyosarcoma, NOS	1	4	5
		8910 Embryonal rhabdomyosarcoma, NOS	7	2	9
		8920 Alveolar rhabdomyosarcoma	0	1	1
b	Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms	8811 Fibromyxosarcoma	1	0	1
d	Other specified soft tissue sarcomas	8806 Desmoplastic small round cell tumor	0	1	1
		9040 Synovial sarcoma, NOS	1	0	1
		9043 Synovial sarcoma, biphasic	0	1	1
		9130 Hemangioendothelioma, malignant	0	1	1
		9581 Alveolar soft part sarcoma	0	1	1
e	Unspecified soft tissue sarcomas	8803 Small cell sarcoma	0	1	1
Total			10	12	22

Site Group		ICD - O - 3 Histology		Male	Female	Total
X	Germ cell tumours, trophoblastic tumours, and neoplasms of gonads					
a	Intracranial and intraspinal germ cell tumours	9064	Germinoma	1	0	1
		9080	Teratoma, malignant, NOS	0	1	1
b	Malignant extracranial and extragonadal germ cell tumours	9064	Germinoma	0	1	1
		9071	Yolk sac tumor	2	2	4
		9080	Teratoma, malignant, NOS	2	3	5
c	Malignant gonadal germ cell tumours	9060	Dysgerminoma	0	1	1
		9071	Yolk sac tumor	2	1	3
		9080	Teratoma, malignant, NOS	1	1	2
		9085	Mixed germ cell tumor	1	4	5
e	Other and unspecified malignant gonadal tumours	8620	Granulosa cell tumor, malignant	0	1	1
Total				9	15	24
XI	Other malignant epithelial neoplasms and malignant melanomas					
a	Adrenocortical carcinoma	8370	Adrenal cortical carcinoma	1	0	1
b	Thyroid carcinoma	8260	Papillary adenocarcinoma, NOS	3	4	7
		8340	Papillary carcinoma, follicular variant	2	1	3
		8341	Papillary microcarcinoma	0	1	1
f	Other and unspecified carcinomas	8200	Adenoid cystic carcinoma	1	0	1
		8310	Clear cell adenocarcinoma, NOS	0	1	1
		8430	Mucoepidermoid carcinoma	1	1	2
		8502	Secretory carcinoma of breast	1	0	1
Total				9	8	17
XII	Other and unspecified neoplasms					
a	Other specified malignant tumours	8973	Pleuropulmonary blastoma	0	1	1
b	Other Unspecified malignant tumours	8000	Neoplasm, malignant	0	1	1
Total				0	2	2
All sites				211	218	429

Table 37: Cancer incidence by geographical area - 2011

Province	District	Male		Female		Total	
		No	%	No	%	No	%
	Not known	1,494	17.8	1,079	11.8	2,573	14.7
Western		2,195	26.2	2,667	29.3	4,862	27.8
	Colombo	913	10.9	1164	12.8	2,077	11.9
	Gampaha	841	10.0	956	10.5	1,797	10.3
	Kalutara	441	5.3	547	6.0	988	5.7
Central		958	11.4	1,234	13.5	2,192	12.5
	Kandy	601	7.2	775	8.5	1,376	7.9
	Matale	185	2.2	185	2.0	370	2.1
	Nuwara Eliya	172	2.1	274	3.0	446	2.6
Southern		762	9.1	849	9.3	1,611	9.2
	Galle	348	4.2	376	4.1	724	4.1
	Hambantota	169	2.0	198	2.2	367	2.1
	Matara	245	2.9	275	3.0	520	3.0
Northern		175	2.1	338	3.7	513	2.9
	Jaffna	104	1.2	204	2.2	308	1.8
	Kilinochchi	12	0.1	23	0.3	35	0.2
	Mannar	17	0.2	31	0.3	48	0.3
	Mullativu	16	0.2	25	0.3	41	0.2
	Vavuniya	26	0.3	55	0.6	81	0.5
Eastern		346	4.1	411	4.5	757	4.3
	Ampara	145	1.7	185	2.0	330	1.9
	Bataloa	119	1.4	151	1.7	270	1.5
	Trincomalee	82	1.0	75	0.8	157	0.9
North western		962	11.5	914	10.0	1,876	10.7
	Kurunegala	699	8.4	628	6.9	1,327	7.6
	Puttalam	263	3.1	286	3.1	549	3.1
North Central		397	4.7	407	4.5	804	4.6
	Anuradhapura	303	3.6	275	3.0	578	3.3
	Polonnaruwa	94	1.1	132	1.4	226	1.3
Uva		383	4.6	441	4.8	824	4.7
	Badulla	266	3.2	311	3.4	577	3.3
	Moneragala	117	1.4	130	1.4	247	1.4
Sabaragamuwa		698	8.3	772	8.5	1,470	8.4
	Ratnapura	375	4.5	430	4.7	805	4.6
	Kegalle	323	3.9	342	3.8	665	3.8
Total		8,370	100.0	9,112	100.0	17,482	100.0

Table 38: Cancer Incidence data by district - 2011**Western Province****Colombo**

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	381	14.6	18.3
2	C00-C06 Lip, tongue and mouth	148	5.7	7.1
3	C18-C20 Colon and rectum	138	5.3	6.6
4	C33-C34 Trachea, bronchus and lung	122	4.7	5.9
5	C53 Cervix uteri	117	4.5	5.6
6	C81-C85, C96 Lymphoma	117	4.5	5.6
7	C91-C95 Leukaemia	102	3.9	4.9
8	C73 Thyroid gland	98	3.8	4.7
9	C56 Ovary	89	3.4	4.3
10	C61 Prostate gland	86	3.3	4.1
	All sites	2,077	79.7	100.0

Gampaha

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	331	15.1	18.4
2	C00-C06 Lip, tongue and mouth	188	8.6	10.5
3	C18-C20 Colon and rectum	121	5.5	6.7
4	C33-C34 Trachea, bronchus and lung	110	5.0	6.1
5	C56 Ovary	95	4.3	5.3
6	C91-C95 Leukaemia	86	3.9	4.8
7	C73 Thyroid gland	84	3.8	4.7
8	C81-C85, C96 Lymphoma	80	3.7	4.5
9	C53 Cervix uteri	67	3.1	3.7
10	C26, C39, C48, C76, C80 Other and unspecified	61	2.8	3.4
	All sites	1,797	82.1	100.0

Kalutara

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	158	13.7	16.0
2	C00-C06 Lip, tongue and mouth	92	8.0	9.3
3	C18-C20 Colon and rectum	66	5.7	6.7
4	C73 Thyroid gland	61	5.3	6.2
5	C53 Cervix uteri	55	4.8	5.6
6	C56 Ovary	51	4.4	5.2
7	C81-C85, C96 Lymphoma	44	3.8	4.5
8	C15 Oesophagus	41	3.6	4.1
9	C33-C34 Trachea, bronchus and lung	40	3.5	4.0
10	C91-C95 Leukaemia	39	3.4	3.9
	All sites	988	85.8	100.0

Central Province

Kandy

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	209	14.4	15.2
2	C15 Oesophagus	142	9.8	10.3
3	C33-C34 Trachea, bronchus and lung	97	6.7	7.0
4	C18-C20 Colon and rectum	81	5.6	5.9
5	C26, C39, C48, C76, C80 Other and unspecified	81	5.6	5.9
6	C00-C06 Lip, tongue and mouth	78	5.4	5.7
7	C73 Thyroid gland	69	4.7	5.0
8	C56 Ovary	67	4.6	4.9
9	C53 Cervix uteri	65	4.5	4.7
10	C81-C85, C96 Lymphoma	58	4.0	4.2
	All sites	1,376	94.6	100.0

Matale

Rank	ICD 10 code and site	Cases	CR	%
1	C15 Oesophagus	43	8.5	11.6
2	C50 Breast	42	8.3	11.4
3	C33-C34 Trachea, bronchus and lung	36	7.2	9.7
4	C00-C06 Lip, tongue and mouth	25	5.0	6.8
5	C18-C20 Colon and rectum	21	4.2	5.7
6	C26, C39, C48, C76, C80 Other and unspecified	21	4.2	5.7
7	C81-C85, C96 Lymphoma	19	3.8	5.1
8	C73 Thyroid gland	15	3.0	4.1
9	C91-C95 Leukaemia	15	3.0	4.1
10	C56 Ovary	14	2.8	3.8
	All sites	370	73.6	100.0

Nuwara Eliya

Rank	ICD 10 code and site	Cases	CR	%
1	C15 Oesophagus	67	8.7	15.0
2	C50 Breast	59	7.7	13.2
3	C00-C06 Lip, tongue and mouth	37	4.8	8.3
4	C16 Stomach	31	4.0	7.0
5	C53 Cervix uteri	29	3.8	6.5
6	C18-C20 Colon and rectum	27	3.5	6.1
7	C26, C39, C48, C76, C80 Other and unspecified	19	2.5	4.3
8	C33-C34 Trachea, bronchus and lung	19	2.5	4.3
9	C81-C85, C96 Lymphoma	17	2.2	3.8
10	C56 Ovary	15	2.0	3.4
	All sites	446	58	100.0

Southern Province

Galle

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	103	9.4	14.2
2	C00-C06 Lip, tongue and mouth	80	7.3	11.0
3	C18-C20 Colon and rectum	61	5.6	8.4
4	C33-C34 Trachea, bronchus and lung	50	4.6	6.9
5	C73 Thyroid gland	49	4.5	6.8
6	C15 Oesophagus	40	3.7	5.5
7	C91-C95 Leukaemia	29	2.7	4.0
8	C53 Cervix uteri	28	2.6	3.9
9	C32 Larynx	26	2.4	3.6
10	C81-C85, C96 Lymphoma	26	2.4	3.6
	All sites	724	66.2	100.0

Hambantota

Rank	ICD 10 code and site	Cases	CR	%
1	C00-C06 Lip, tongue and mouth	60	10.4	16.3
2	C73 Thyroid gland	45	7.8	12.3
3	C50 Breast	39	6.8	10.6
4	C53 Cervix uteri	24	4.2	6.5
5	C18-C20 Colon and rectum	23	4.0	6.3
6	C33-C34 Trachea, bronchus and lung	21	3.6	5.7
7	C81-C85, C96 Lymphoma	17	2.9	4.6
8	C91-C95 Leukaemia	16	2.8	4.4
9	C56 Ovary	13	2.3	3.5
10	C15 Oesophagus	12	2.1	3.3
	All sites	367	63.6	100.0

Matara

Rank	ICD 10 code and site	Cases	CR	%
1	C00-C06 Lip, tongue and mouth	84	9.9	16.2
2	C50 Breast	63	7.4	12.1
3	C18-C20 Colon and rectum	32	3.8	6.2
4	C73 Thyroid gland	32	3.8	6.2
5	C81-C85, C96 Lymphoma	28	3.3	5.4
6	C26, C39, C48, C76, C80 Other and unspecified	25	3.0	4.8
7	C53 Cervix uteri	25	3.0	4.8
8	C15 Oesophagus	22	2.6	4.2
9	C33-C34 Trachea, bronchus and lung	20	2.4	3.8
10	C56 Ovary	19	2.2	3.7
	All sites	520	61.4	100.0

Northern Province

Jaffna

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	59	10.9	19.2
2	C00-C06 Lip, tongue and mouth	36	6.6	11.7
3	C15 Oesophagus	34	6.3	11.0
4	C56 Ovary	24	4.4	7.8
5	C18-C20 Colon and rectum	21	3.9	6.8
6	C53 Cervix uteri	17	3.1	5.5
7	C73 Thyroid gland	17	3.1	5.5
8	C81-C85, C96 Lymphoma	10	1.8	3.2
9	C91-C95 Leukaemia	10	1.8	3.2
10	C32 Larynx	9	1.7	2.9
	All sites	308	56.8	100.0

Killinochchi

Rank	ICD 10 code and site	Cases	CR	%
1	C53 Cervix uteri	5	3.2	14.3
2	C73 Thyroid gland	4	2.6	11.4
3	C50 Breast	3	1.9	8.6
4	C00-C06 Lip, tongue and mouth	2	1.3	5.7
5	C56 Ovary	2	1.3	5.7
6	C61 Prostate gland	2	1.3	5.7
7	C81-C85, C96 Lymphoma	2	1.3	5.7
8	C12-C13 Hypopharynx	1	0.6	2.9
9	C15 Oesophagus	1	0.6	2.9
10	C18-C20 Colon and rectum	1	0.6	2.9
	All sites	35	22.7	100.0

Mannar

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	12	7.4	25.0
2	C53 Cervix uteri	5	3.1	10.4
3	C73 Thyroid gland	4	2.5	8.3
4	C15 Oesophagus	3	1.8	6.3
5	C18-C20 Colon and rectum	3	1.8	6.3
6	C00-C06 Lip, tongue and mouth	2	1.2	4.2
7	C10 Other oropharynx	2	1.2	4.2
8	C33-C34 Trachea, bronchus and lung	2	1.2	4.2
9	C54-C55 Uterus	2	1.2	4.2
10	C56 Ovary	2	1.2	4.2
	All sites	48	29.4	100.0

Mullativu

Rank	ICD 10 code and site	Cases	CR	%
1	C00-C06 Lip, tongue and mouth	9	7.2	22.0
2	C50 Breast	6	4.8	14.6
3	C53 Cervix uteri	5	4.0	12.2
4	C15 Oesophagus	4	3.2	9.8
5	C12-C13 Hypopharynx	2	1.6	4.9
6	C26, C39, C48, C76, C80 Other and unspecified	2	1.6	4.9
7	C61 Prostate gland	2	1.6	4.9
8	C91-C95 Leukaemia	2	1.6	4.9
9	C09 Tonsil	1	0.8	2.4
10	C18-C20 Colon and rectum	1	0.8	2.4
	All sites	41	32.8	100.0

Vavuniya

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	18	10.2	22.2
2	C53 Cervix uteri	7	4.0	8.6
3	C00-C06 Lip, tongue and mouth	6	3.4	7.4
4	C73 Thyroid gland	6	3.4	7.4
5	C33-C34 Trachea, bronchus and lung	6	3.4	7.4
6	C91-C95 Leukaemia	5	2.8	6.2
7	C15 Oesophagus	5	2.8	6.2
8	C54-C55 Uterus	5	2.8	6.2
9	C16 Stomach	4	2.3	4.9
10	C32 Larynx	3	1.7	3.7
	All sites	81	46	100.0

Eastern Province

Ampara

Rank	ICD 10 code and site		Cases	CR	%
1	C50	Breast	49	7.5	14.8
2	C33-C34	Trachea, bronchus and lung	33	5.0	10.0
3	C00-C06	Lip, tongue and mouth	32	4.9	9.7
4	C73	Thyroid gland	24	3.7	7.3
5	C18-C20	Colon and rectum	18	2.8	5.5
6	C53	Cervix uteri	17	2.6	5.2
7	C81-C85, C96	Lymphoma	17	2.6	5.2
8	C91-C95	Leukaemia	16	2.4	4.8
9	C15	Oesophagus	14	2.1	4.2
10	C56	Ovary	14	2.1	4.2
	All sites		330	50.5	100.0

Batticaloa

Rank	ICD 10 code and site		Cases	CR	%
1	C00-C06	Lip, tongue and mouth	49	8.9	18.1
2	C50	Breast	27	4.9	10.0
3	C53	Cervix uteri	27	4.9	10.0
4	C91-C95	Leukaemia	20	3.6	7.4
5	C73	Thyroid gland	19	3.5	7.0
6	C81-C85, C96	Lymphoma	15	2.7	5.6
7	C15	Oesophagus	14	2.6	5.2
8	C33-C34	Trachea, bronchus and lung	12	2.2	4.4
9	C56	Ovary	12	2.2	4.4
10	C18-C20	Colon and rectum	11	2.0	4.1
	All sites		270	49.2	100.0

Trincomalee

Rank	ICD 10 code and site		Cases	CR	%
1	C50	Breast	19	5.0	12.1
2	C00-C06	Lip, tongue and mouth	17	4.5	10.8
3	C91-C95	Leukaemia	14	3.7	8.9
4	C53	Cervix uteri	10	2.6	6.4
5	C73	Thyroid gland	10	2.6	6.4
6	C70-C72	Brain and nervous system	9	2.4	5.7
7	C26, C39, C48, C76, C80	Other and unspecified	8	2.1	5.1
8	C32	Larynx	8	2.1	5.1
9	C33-C34	Trachea, bronchus and lung	7	1.8	4.5
10	C81-C85, C96	Lymphoma	7	1.8	4.5
	All sites		157	41.2	100.0

North Western Province

Kurunegala

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	174	11.0	13.1
2	C00-C06 Lip, tongue and mouth	156	9.9	11.8
3	C15 Oesophagus	118	7.5	8.9
4	C18-C20 Colon and rectum	76	4.8	5.7
5	C81-C85, C96 Lymphoma	69	4.4	5.2
6	C53 Cervix uteri	66	4.2	5.0
7	C33-C34 Trachea, bronchus and lung	64	4.0	4.8
8	C73 Thyroid gland	61	3.9	4.6
9	C32 Larynx	60	3.8	4.5
10	C56 Ovary	55	3.5	4.1
	All Sites	1,327	83.8	100.0

Puttalam

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	78	9.8	14.2
2	C00-C06 Lip, tongue and mouth	65	8.2	11.8
3	C53 Cervix uteri	38	4.8	6.9
4	C73 Thyroid gland	34	4.3	6.2
5	C15 Oesophagus	27	3.4	4.9
6	C81-C85, C96 Lymphoma	24	3.0	4.4
7	C18-C20 Colon and rectum	23	2.9	4.2
8	C26, C39, C48, C76, C80 Other and unspecified	22	2.8	4.0
9	C91-C95 Leukaemia	22	2.8	4.0
10	C33-C34 Trachea, bronchus and lung	21	2.6	3.8
	All sites	549	69.1	100.0

North Central Province

Anuradhapura

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	72	8.6	12.5
2	C33-C34 Trachea, bronchus and lung	55	6.6	9.5
3	C00-C06 Lip, tongue and mouth	49	5.8	8.5
4	C15 Oesophagus	43	5.1	7.4
5	C18-C20 Colon and rectum	40	4.8	6.9
6	C91-C95 Leukaemia	30	3.6	5.2
7	C56 Ovary	27	3.2	4.7
8	C26, C39, C48, C76, C80 Other and unspecified	25	3.0	4.3
9	C81- C85, C96 Lymphoma	25	3.0	4.3
10	C53 Cervix uteri	24	2.9	4.2
	All sites	578	68.9	100.0

Polonnaruwa

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	31	7.5	13.7
2	C73 Thyroid gland	21	5.1	9.3
3	C18-C20 Colon and rectum	18	4.3	8.0
4	C00-C06 Lip, tongue and mouth	17	4.1	7.5
5	C15 Oesophagus	17	4.1	7.5
6	C53 Cervix uteri	16	3.9	7.1
7	C33-C34 Trachea, bronchus and lung	15	3.6	6.6
8	C91-C95 Leukaemia	14	3.4	6.2
9	C26, C39, C48, C76, C80 Other and unspecified	11	2.7	4.9
10	C70-C72 Brain and nervous system	7	1.7	3.1
	All sites	226	54.5	100.0

Uva Province

Badulla

Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	80	8.9	13.9
2	C00-C06 Lip, tongue and mouth	72	8.0	12.5
3	C15 Oesophagus	41	4.5	7.1
4	C73 Thyroid gland	41	4.5	7.1
5	C33-C34 Trachea, bronchus and lung	33	3.7	5.7
6	C53 Cervix uteri	30	3.3	5.2
7	C91-C95 Leukaemia	28	3.1	4.9
8	C18-C20 Colon and rectum	27	3.0	4.7
9	C16 Stomach	21	2.3	3.6
10	C56 Ovary	21	2.3	3.6
	All sites	577	64.0	100.0

Moneragala

Rank	ICD 10 code and site	Cases	CR	%
1	C00-C06 Lip, tongue and mouth	36	8.1	14.6
2	C73 Thyroid gland	31	6.9	12.6
3	C53 Cervix uteri	19	4.3	7.7
4	C50 Breast	18	4.0	7.3
5	C33-C34 Trachea, bronchus and lung	18	4.0	7.3
6	C18-C20 Colon and rectum	17	3.8	6.9
7	C15 Oesophagus	15	3.4	6.1
8	C91-C95 Leukaemia	10	2.2	4.0
9	C56 Ovary	10	2.2	4.0
10	C81-C85, C96 Lymphoma	10	2.2	4.0
	All sites	247	55.3	100.0

Sabaragamuwa Province


Kegalle



Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	91	11.0	13.7
2	C00-C06 Lip, tongue and mouth	80	9.7	12.0
3	C15 Oesophagus	59	7.1	8.9
4	C18-C20 Colon and rectum	41	5.0	6.2
5	C26, C39, C48, C76, C80 Other and unspecified	37	4.5	5.6
6	C91-C95 Leukaemia	33	4.0	5.0
7	C81-C85, C96 Lymphoma	32	3.9	4.8
8	C33-C34 Trachea, bronchus and lung	31	3.7	4.7
9	C53 Cervix uteri	31	3.7	4.7
10	C73 Thyroid gland	25	3.0	3.8
	All sites	665	80.3	100.0

Ratnapura


Rank	ICD 10 code and site	Cases	CR	%
1	C50 Breast	118	10.3	14.7
2	C00-C06 Lip, tongue and mouth	97	8.4	12.0
3	C15 Oesophagus	57	5.0	7.1
4	C91-C95 Leukaemia	54	4.7	6.7
5	C18-C20 Colon and rectum	47	4.1	5.8
6	C53 Cervix uteri	43	3.7	5.3
7	C73 Thyroid gland	39	3.4	4.8
8	C33-C34 Trachea, bronchus and lung	35	3.0	4.3
9	C56 Ovary	35	3.0	4.3
10	C81-C85, C96 Lymphoma	33	2.9	4.1
	All sites	805	70.1	100.0

Figure 55: Cancer incidence by district - Male 2011







Leukaemia (Male)




Lymphoma (Male)




Lip, Tongue and Mouth
(Female)




Uterus
(Female)




Trachea, Bronchus and Lung (Male & Female)



Colon and Rectum (Male & Female)



**Thyroid Gland
(Male & Female)**



List of References

- Cancer Registry, National Cancer Control Programme (2016), Cancer Incidence Data, Sri Lanka, 2010
- Cancer Registry, National Cancer Control Programme (2015), Cancer Incidence Data, Sri Lanka, 2009
- Cancer Registry, National Cancer Control Programme (2014), Cancer Incidence Data, Sri Lanka, 2008
- Cancer Registry, National Cancer Control Programme (2013), Cancer Incidence Data, Sri Lanka, 2007
- Cancer Registry, National Cancer Control Programme (2012), Cancer Incidence Data; Sri Lanka 2006
- Cancer Registry, National Cancer Control Programme (2009), Cancer Incidence Data; Sri Lanka 2001 - 2005
- Cancer Registry, National Cancer Control Programme (2005), Cancer Incidence Data; Sri Lanka 2000
- Cancer Registry, National Cancer Control Programme (2002), Cancer Incidence 1995; Sri Lanka
- Cancer Registry, National Cancer Control Programme (1996), Cancer Incidence in Sri Lanka 1990; Sri Lanka
- Cancer Registry, National Cancer Control Programme (1990), Cancer Incidence in Sri Lanka 1985; Sri Lanka
- Department of Census and Statistics; Estimated midyear population by sex and age group, 2011 - 2015
<http://www.statistics.gov.lk/PopHouSat/VitalStatistics/MidYearPopulation/Mid-year%20population%20by%20age%20group.pdf> [30 June 2018]
- Department of Census and Statistics; Estimated midyear population by district 2011 - 2015
<http://www.statistics.gov.lk/PopHouSat/VitalStatistics/MidYearPopulation/Mid-year%20population%20by%20district.pdf> [30 June 2018]
- Doll, R., Payne, p., Waterhouse, J.A.H.eds (1966). Cancer Incidence in Five Continents, Vol. 10 Union International Centre le Cancer, Geneva.
https://www.iarc.fr/wp-content/uploads/2018/07/Ci5volX_Full.pdf [30 November 2018]
- Fritz, A. Percy. C. Jack, A.Shanmugaratnam, K.Sobin, L.Parkin, D.M.Whelan s. (ed) (2009) International Classification of Diseases of Oncology, 3rd Edition WHO, Geneva
- Glossary of statistical terms; <http://www-dep.iarc.fr/NORDCAN/english/glossary.htm> [01 Dec 2011]
- ICD 10-10th revision, Fifth edition 2016, World Health Organization
<https://www.who.int/classifications/icd/icdonlineversions/en/> [30 November 2018]
- International Classification of Childhood Cancer, Third Edition, *Cancer 2005*; 103: 1457-67
- Indian Cancer Society, Parel, Mumbai, India (2009) Cancer Incidence and Mortality in Greater Mumbai, 2005
- K.S.Chia, A.Seow, H.P.Lee, K. Shanmugaratnam; (2009) Cancer Incidence in Singapore 1993-1997; Singapore Cancer Registry
- Medical Statistics Unit, Ministry of Health, Sri Lanka (2008) Annual Health Bulletin, Sri Lanka 2005 to 2011
- National Cancer Centre, Ministry of Health and Welfare, Republic of Korea (2011) Cancer Facts & Figures 2011 Segi, M. (1960)
- National Centre for Disease Informatics and Research, Three –year Report of Population Based Cancer Registries: 2012-2014.Report of 27 PBCR in India.

Appendix - Statistical Terminology

Population at risk

The population at risk includes all individuals susceptible to a specific cancer. It is defined on the basis of demographic variables, such as place of residence, sex, age group. Years of risk duration are counted in person-years.

Incidence

Incidence quantifies the number of new cases that develop in a population of individuals at risk during a specified time interval. Usually it is given as per 100,000 population per year.

Mortality

Mortality is the number of deaths occurring in a given period in a specified population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year.

Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk.

$$\text{Crude incidence rate} = \frac{\text{Total number of cases in the year}}{\text{Total midyear population at risk}} \times 100,000$$

$$\text{Crude death rate} = \frac{\text{Total number of deaths in the year}}{\text{Total midyear population at risk}} \times 100,000$$

Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five- year age categories are used

$$\text{Age-specific incidence rate} = \frac{\text{Number of cases in the five-year age group}}{\text{Population at risk in the corresponding age group}} \times 100,000$$

$$\text{Age-specific death rate} = \frac{\text{Number of deaths in the five-year age group}}{\text{Population at risk in the corresponding age group}} \times 100,000$$

ASR (Age standardized rate)

An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with

respect to age because age has a powerful influence on the risk of dying from cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the *standard population*. The most frequently used standard population is the *World Standard Population*. The calculated mortality rate is then called age-standardised mortality rate (world). The world standard population used within the application is as proposed by Segi (1960) and modified by Doll and *al.* (1966). The ASR is also expressed per 100,000.

Age group	w_i
0-4	12000
5-9	10000
10-14	9000
15-19	9000
20-24	8000
25-29	8000
30-34	6000
35-39	6000
40-44	6000
45-49	6000
50-54	5000
55-59	4000
60-64	4000
65-69	3000
70-74	2000
75-79	1000
80-84	500
85+	500
Total	100000

Life time risk (Cumulative Risk)

Cumulative incidence/mortality is the probability or risk of individuals getting/dying from the disease within a specified age interval within a time period.

(The cumulative risk is the risk which an individual would have of developing the cancer under study during a certain age span if no other causes of death were in operation)

Reference: Glossary of Terms, <http://www-dep.iarc.fr/WHOdb/glossary.htm> [30 November 2018]



National Cancer Control Programme
555, Elvitigala Mawatha
Colombo 5
Sri Lanka

